WO2014100913A1 - Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer - Google Patents
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer Download PDFInfo
- Publication number
- WO2014100913A1 WO2014100913A1 PCT/CN2012/001723 CN2012001723W WO2014100913A1 WO 2014100913 A1 WO2014100913 A1 WO 2014100913A1 CN 2012001723 W CN2012001723 W CN 2012001723W WO 2014100913 A1 WO2014100913 A1 WO 2014100913A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- fusion protein
- flexible
- glp
- human
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 134
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 129
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 127
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 87
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 title claims abstract description 78
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 title claims abstract description 78
- 101710204410 Scaffold protein Proteins 0.000 title claims abstract description 78
- 125000006850 spacer group Chemical group 0.000 title claims abstract description 45
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 141
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 102200069889 rs104893964 Human genes 0.000 claims description 121
- 108090000623 proteins and genes Proteins 0.000 claims description 107
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims description 78
- 102220139548 rs61735306 Human genes 0.000 claims description 64
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 53
- 239000013638 trimer Substances 0.000 claims description 46
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 42
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 41
- 239000013604 expression vector Substances 0.000 claims description 31
- 102000008186 Collagen Human genes 0.000 claims description 29
- 108010035532 Collagen Proteins 0.000 claims description 29
- 102000002090 Fibronectin type III Human genes 0.000 claims description 29
- 229920001436 collagen Polymers 0.000 claims description 29
- -1 cbln family members Proteins 0.000 claims description 27
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 26
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 24
- 229960001319 parathyroid hormone Drugs 0.000 claims description 24
- 239000000199 parathyroid hormone Substances 0.000 claims description 24
- 238000001727 in vivo Methods 0.000 claims description 23
- 108050009401 Fibronectin type III Proteins 0.000 claims description 18
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 16
- 102000011690 Adiponectin Human genes 0.000 claims description 15
- 108010076365 Adiponectin Proteins 0.000 claims description 15
- 108010087870 Mannose-Binding Lectin Proteins 0.000 claims description 15
- 102000009112 Mannose-Binding Lectin Human genes 0.000 claims description 15
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 15
- 102000004405 Collectins Human genes 0.000 claims description 12
- 108090000909 Collectins Proteins 0.000 claims description 12
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 12
- 102000014128 RANK Ligand Human genes 0.000 claims description 11
- 108010025832 RANK Ligand Proteins 0.000 claims description 11
- 102000055006 Calcitonin Human genes 0.000 claims description 9
- 108060001064 Calcitonin Proteins 0.000 claims description 9
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 9
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 9
- 108091008605 VEGF receptors Proteins 0.000 claims description 9
- 229960004015 calcitonin Drugs 0.000 claims description 9
- 102000058004 human PTH Human genes 0.000 claims description 9
- 101100328883 Arabidopsis thaliana COL1 gene Proteins 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims description 6
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 claims description 6
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 claims description 6
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 claims description 6
- 102100038803 Somatotropin Human genes 0.000 claims description 6
- 102000011408 Tripartite Motif Proteins Human genes 0.000 claims description 6
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000000122 growth hormone Substances 0.000 claims description 6
- 102000002086 C-type lectin-like Human genes 0.000 claims description 5
- 108050009406 C-type lectin-like Proteins 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 5
- 102000003951 Erythropoietin Human genes 0.000 claims description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940105423 erythropoietin Drugs 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 claims description 4
- 101000666340 Homo sapiens Tenascin Proteins 0.000 claims description 4
- 102100040918 Pro-glucagon Human genes 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 102000007000 Tenascin Human genes 0.000 claims description 4
- 108010008125 Tenascin Proteins 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 102000057345 human TNC Human genes 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 102100031793 Adipolin Human genes 0.000 claims description 3
- 101710099074 Adipolin Proteins 0.000 claims description 3
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 3
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 claims description 3
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 claims description 3
- 102000007499 CD27 Ligand Human genes 0.000 claims description 3
- 108010046080 CD27 Ligand Proteins 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 108010002947 Connectin Proteins 0.000 claims description 3
- 102000004726 Connectin Human genes 0.000 claims description 3
- 102000018361 Contactin Human genes 0.000 claims description 3
- 108060003955 Contactin Proteins 0.000 claims description 3
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 3
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 3
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 claims description 3
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 claims description 3
- 101001037246 Homo sapiens Interleukin-27 receptor subunit alpha Proteins 0.000 claims description 3
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 3
- 101000581984 Homo sapiens Neural cell adhesion molecule 2 Proteins 0.000 claims description 3
- 101000651178 Homo sapiens Striated muscle preferentially expressed protein kinase Proteins 0.000 claims description 3
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 3
- 108010001127 Insulin Receptor Proteins 0.000 claims description 3
- 102100036721 Insulin receptor Human genes 0.000 claims description 3
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims description 3
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 claims description 3
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 3
- 102100040066 Interleukin-27 receptor subunit alpha Human genes 0.000 claims description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- 102100031775 Leptin receptor Human genes 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims description 3
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 claims description 3
- 102100023354 Multimerin-1 Human genes 0.000 claims description 3
- 102100032971 Myomesin-1 Human genes 0.000 claims description 3
- 101710106571 Myomesin-1 Proteins 0.000 claims description 3
- 102100032965 Myomesin-2 Human genes 0.000 claims description 3
- 101710106572 Myomesin-2 Proteins 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100030467 Neural cell adhesion molecule 2 Human genes 0.000 claims description 3
- 108010042215 OX40 Ligand Proteins 0.000 claims description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 3
- 108010002519 Prolactin Receptors Proteins 0.000 claims description 3
- 102100029000 Prolactin receptor Human genes 0.000 claims description 3
- 101710089914 Receptor-type tyrosine-protein phosphatase Proteins 0.000 claims description 3
- 108010047909 Resistin Proteins 0.000 claims description 3
- 102000007156 Resistin Human genes 0.000 claims description 3
- 108010068542 Somatotropin Receptors Proteins 0.000 claims description 3
- 102100027659 Striated muscle preferentially expressed protein kinase Human genes 0.000 claims description 3
- 108700012411 TNFSF10 Proteins 0.000 claims description 3
- 102100024554 Tetranectin Human genes 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 102100030859 Tissue factor Human genes 0.000 claims description 3
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 3
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 3
- 101710138401 Usherin Proteins 0.000 claims description 3
- 102100037930 Usherin Human genes 0.000 claims description 3
- 108010018927 conglutinin Proteins 0.000 claims description 3
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 claims description 3
- 108700004389 elastin microfibril interface located Proteins 0.000 claims description 3
- 108091008790 ephrin type A receptors Proteins 0.000 claims description 3
- 108091008789 ephrin type B receptors Proteins 0.000 claims description 3
- 102000057041 human TNF Human genes 0.000 claims description 3
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 3
- 108010019813 leptin receptors Proteins 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 108010012891 multimerin Proteins 0.000 claims description 3
- 108010059725 myosin-binding protein C Proteins 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 108010013645 tetranectin Proteins 0.000 claims description 3
- 102000035160 transmembrane proteins Human genes 0.000 claims description 3
- 108091005703 transmembrane proteins Proteins 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101800000618 Protein kinase C delta type catalytic subunit Proteins 0.000 claims description 2
- 102100021004 Protein sidekick-1 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 101000716310 Homo sapiens Protein sidekick-2 Proteins 0.000 claims 2
- 102100021005 Protein sidekick-2 Human genes 0.000 claims 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 2
- 102100024206 Collectin-10 Human genes 0.000 claims 1
- 101710194645 Collectin-10 Proteins 0.000 claims 1
- 102100024330 Collectin-12 Human genes 0.000 claims 1
- 101710194650 Collectin-12 Proteins 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 101150087500 Gpl gene Proteins 0.000 claims 1
- 101001003142 Homo sapiens Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 102100021596 Interleukin-31 Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 48
- 150000007523 nucleic acids Chemical class 0.000 abstract description 13
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 235000018102 proteins Nutrition 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 59
- 230000004927 fusion Effects 0.000 description 34
- 239000000243 solution Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- 230000004071 biological effect Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 230000006320 pegylation Effects 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 102000047200 Collagen Type XVIII Human genes 0.000 description 10
- 108010001463 Collagen Type XVIII Proteins 0.000 description 10
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 10
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010008165 Etanercept Proteins 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000003259 recombinant expression Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 238000001712 DNA sequencing Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108010068072 salmon calcitonin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 5
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 108700005078 Synthetic Genes Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000013262 cAMP assay Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229960000403 etanercept Drugs 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 108020001580 protein domains Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005829 trimerization reaction Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108050001049 Extracellular proteins Proteins 0.000 description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 description 3
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 3
- 101000899935 Homo sapiens Collagen alpha-1(XV) chain Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 229940073621 enbrel Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000057799 human ADIPOQ Human genes 0.000 description 3
- 102000057622 human COL15A1 Human genes 0.000 description 3
- 102000054700 human collagen XIX Human genes 0.000 description 3
- 108700012815 human collagen XIX Proteins 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000013878 renal filtration Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100192865 Drosophila melanogaster GlyP gene Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000009842 Fibril-Associated Collagens Human genes 0.000 description 1
- 108010020305 Fibril-Associated Collagens Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 1
- 101500028773 Homo sapiens Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101100286681 Homo sapiens IL13 gene Proteins 0.000 description 1
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 101000648503 Homo sapiens Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 1
- 101000753253 Homo sapiens Tyrosine-protein kinase receptor Tie-1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100026011 Interleukin-13 Human genes 0.000 description 1
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108060009345 SORL1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102100025639 Sortilin-related receptor Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical class C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 102000055590 human KDR Human genes 0.000 description 1
- 102000053530 human TNFRSF11A Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108010087558 pectate lyase Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 108700002854 polyethylene glycol(B1)- insulin Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present invention relates generally to a fusion protein with therapeutic efficacy.
- the present invention relates to a method of improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer.
- PEGylation has been widely utilized to extend the half life of a therapeutic polypeptide (see review paper , patents 1-9).
- PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug.
- PEGylation improves drug solubility and decreases immunogenicity.
- PEGylation also increases drug stability and the retention time of the conjugates in blood.
- PEGylation has severe consequences for the biological activities of the protein.
- the activity of the PEGylated protein usually reduces by 20-50 fold 2 ' 5 (patents 1 -9).
- the site for PEGylation needs to be carefully decided to avoid interfering with the active site of the therapeutic polypeptide.
- some short peptides such as GLP- 1 , PTH and Calcitonin, it would be difficult to choose the proper site for PEGylation without disturbing the biological activity of the peptides.
- fusion of a therapeutic polypeptide with human IgG Fc fragment or human serum albumin may significantly increase the half life of the therapeutic polypeptide 6 9 (patents 10, 1 1 , 12).
- recombinant fusion protein with IgG Fc fragment or HSA needs to be produced from eukaryotic systems such as mammalian cell lines or yeast cells, which significantly increases the cost of the recombinant protein.
- the present invention provides a fusion protein comprising a therapeutic polypeptide fused to a scaffold protein which forms a homo-trimer in solution, wherein the therapeutic polypeptide is connected with the scaffold protein via a spacer, and the spacer comprises a flexible un-structured linker whose length is adjustable.
- the spacer further comprises a proteinous connecting moiety.
- the proteinous connecting moiety is a proteinous sequence having an elongated shape, such as human Fibronectin type III domain.
- the proteinous connecting moiety is connected with the therapeutic polypeptide and/or the scaffold protein via a flexible un-structured linker.
- the fusion protein of the invention comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a first flexible un-structured linker (linker 1), a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), a second flexible un-structured linker (linker 2), and the scaffold protein.
- the fusion protein of the invention comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), the flexible un-structured linker, and the scaffold protein.
- the fusion protein of the invention comprises, from N-terminus to C-terminus, the therapeutic polypeptide, the flexible un-structured linker, and the scaffold protein. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the scaffold protein, a first flexible un-structured linker, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), a second flexible un-structured linker, and the therapeutic polypeptide. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the scaffold protein, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), the flexible un-structured linker, and the therapeutic polypeptide. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the scaffold protein, the flexible un-structured linker, and the therapeutic polypeptide.
- the scaffold protein of the invention is selected from the group consisting of human collagen noncollagenous (NC) domains which form stable homo-trimers in solution, proteins which form homo-trimers in solution with C l q-like molecular structures, proteins which form homo-trimers in solution with TNF-like molecular structures, and proteins with C-type lectin-like domains (CTLD) which form homo-trimers in solution.
- NC human collagen noncollagenous domains
- the therapeutic polypeptide is selected from the group consisting of human glucagon-like peptide- 1 (GLP-1 ), Calcitonin, human Parathyroid hormone (PTH), G-CSF, GM-CSF, Interferon, VEGF receptors, TNF alpha receptors, RANK, Growth hormone, Erythropoietin, single-chain Fv, single domain antibodies and functional variants thereof.
- GLP-1 human glucagon-like peptide- 1
- PTH human Parathyroid hormone
- G-CSF human Parathyroid hormone
- GM-CSF GM-CSF
- Interferon Interferon
- VEGF receptors vascular endothelial growth factor receptors
- TNF alpha receptors RANK
- Growth hormone Erythropoietin
- single-chain Fv single domain antibodies and functional variants thereof.
- the fusion protein of the invention comprises: a therapeutic polypeptide selected from the group consisting of GLP- 1 , GLP 1 (A8G/G22E) and GLP 1(A8G/G22E R36S); a first flexible un-structured linker; a proteinous connecting moiety selected from the group consisting of Fn7, Fn8 and TNCfn3, a second flexible un-structured linker; and a scaffold protein selected from the group consisting of COL 18NC1 , COL15NC1 , COL19NC2, ACRP30 C l q-like domain, and MBL neck and CRD domain.
- the fusion protein of the invention comprises: GLP 1 (A8G/G22E/R36S), a first flexible un-structured linker, Fn8, a second flexible un-structured linker, and COL18NC1.
- the present invention also provides a polynucleotide sequence encoding the fusion protein, a pharmaceutical composition comprising the fusion protein and a pharmaceutically acceptable carrier, and an expression vector comprising the polynucleotide sequence and expression control elements.
- the present invention provides a method of improving the pharmacokinetic property of a therapeutic polypeptide, comprising the step of fusing the therapeutic polypeptide to a scaffold protein which forms a homo-trimer in solution, wherein the therapeutic polypeptide is connected with the scaffold protein via a spacer, and the spacer comprises a flexible un-structured linker whose length is adjustable to adjust the apparent molecular size and/or the in vivo half life of the fusion protein.
- Fig. 1 shows the schematic drawings illustrating the mechanisms of the present invention.
- the therapeutic polypeptide is shown as a red star in Fig. l a and as a red helix in Fig. lb, the spacer is shown in blue and the scaffold protein is shown as a grey sphere, a)
- the therapeutic polypeptide can be connected to the scaffold protein by a flexible, unstructured linker as the spacer, b)
- the therapeutic polypeptide can be connected to the scaffold protein by a first flexible unstructured linker (linker 1 ), a proteinous connecting moiety (preferably with an elongated shape, such as Fibronectin type III domain) and a second flexible unstructured linker (linker 2) as the spacer.
- Fig. 2 shows the result of SDS-PAGE analysis of purified proteins.
- GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl ,
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -20
- GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl-30
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
- GLP- l (A8G/G22E/R36S)-Fn8-COL18NCl-60 are shown in lane 1 , 2, 3, 4 and 5.
- the molecular markers are labeled at the left of the 12% gel.
- Fig. 3 shows the gel filtration chromatography profiles for purified GLP-1 (A8G/G22E/R36S)-Fn8-COLl 8NC1 ,
- G LP- 1 ( A8G/G22E/R36S)-Fn8-COLl 8NC 1 -20,
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30, GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
- GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -60 using the analytical column Superdex200 (GE Healthcare).
- the profiles of these proteins are labeled as NCI , NCI -20, NCI -30, NCI -54 and NCI -60.
- the elution time for the molecular marker proteins (158Kd and 44Kd) are shown by arrows.
- the X-axis refers to elution time and the Y-axis refers to UV280 absorbance intensity.
- Fig. 4 shows the results of cAMP assays for GLP- 1 (7-37) peptide, GLP l (A8G/G22E/R36S)-Fn8-NCl and
- GLPl(A8G/G22E/R36S)-Fn8-NCl -54 This assay is based on competitive binding technique.
- a monoclonal antibody specific for cAMP becomes bound to the goat anti-mouse antibody coated onto the microplate.
- cAMP present in a sample competes with a fixed amount of horseradish peroxidase (HRP)-Iabeled cAMP for sites on the monoclonal antibody. This is followed by another wash to remove excess conjugate and unbound sample.
- HRP horseradish peroxidase
- a substrate solution is added to the wells to determine the bound enzyme activity. The color development is stopped and the absorbance is read at 450nm.
- the intensity of the color is inversely proportional to the concentration of cAMP in the sample.
- the Y-axis refers to the OD450 obtained by the plate reader and the X-axis refers to the concentration of GLP-1 (7-37) peptide, GLP l (A8G/G22E R36S)-Fn8-NCl and GLP 1 ( A8G/G22E R36S)-Fn8-NCl -54.
- Fig. 5 shows the pharmacokinetics profiles of the GLP- 1 containing proteins (GLP- l(A8G/G22E/R36S)-Fn8-COL 18NC 1 ,
- GLP-1 (A8G/G22E/R36S)-Fn8-COLl 8NC 1 -20
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COLl 8NC 1 -30 and
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COLl 8NC 1 -54) in rats measured by use of the sandwich ELISA method.
- the profiles of these proteins are labeled as NCI , NC20, NC30 and NC54.
- a method to increase the half life of a therapeutic polypeptide by fusing the therapeutic polypeptide to a scaffold protein via a spacer.
- the scaffold protein can form a stable homo-trimer in solution.
- the therapeutic polypeptide is connected to the scaffold protein through a spacer.
- the spacer may comprise a flexible, un-structured linker whose length is adjustable (Fig. la).
- the spacer may further comprise a proteinous connecting moiety , preferably a proteinous sequence with an elongated shape.
- the proteinous connecting moiety can be connected to the therapeutic polypeptide and/or the scaffold protein via a flexible, un-structured linker whose length is adjustable (Fig. lb).
- This novel method provided by the invention termed as “Trident technology”, can efficiently increase the radius of gyration (Rg) of the polypeptide molecule to extend its half life in vivo. Moreover, changing the length of the spacer can adjust the in vivo half life of the fusion protein in a tunable manner.
- Rg radius of gyration
- the method of the invention may have several major advantages over the traditional PEGylation method or Fc/HSA fusion method.
- PEGylation on the polypeptide molecule is not essential, therefore the biological activity of the therapeutic polypeptide is fully retained.
- the scaffold protein forms a homo-trimer, the fusion protein of the therapeutic polypeptide with the scaffold protein may greatly increase the apparent size of the fusion protein to slow down renal filtration. Moreover, the trimer formation also renders the fusion protein tri-valency. This may greatly increase the activity of the therapeutic protein. 3.
- the length of the spacer between the therapeutic polypeptide and the scaffold protein plays an important role in determining the in vivo half life of the fusion protein.
- the method of the invention provides a platform to fine tune the in vivo half life of a therapeutic polypeptide by varying the length of the spacer within the fusion protein.
- the scaffold protein is preferably selected from human proteins, usually from human extracellular proteins, therefore, no foreign protein sequences are introduced into the fusion protein. The immunogenicity of the fusion proteins generated using the method is low. 5.
- the recombinant fusion protein of the therapeutic polypeptide and the scaffold protein can be generated using E.coli expression system, which eliminates the need of the expensive chemical synthesis process for some therapeutic polypeptides or the need of using the eukaryotic expression systems.
- the scaffold protein is The scaffold protein
- Collagens are a diverse family of proteins that constitute the major structural component of the extracellular matrix 10"12 .
- Collagen is composed of a triple helix, which generally consists of an identical chain (otl ) or an
- Classification according to supramolecular structure assigns collagens to fibril, fibril-associated containing interrupted triple helicies (FACIT), beaded filament, anchoring fibril, network-forming, transmembrane or multiple triple helicies with interruptions (Multiplexin) families 13 .
- FACIT interrupted triple helicies
- Multiplexin multiple triple helicies with interruptions
- the alpha chains of collagens consist of at least one triple helical collagenous domain of varying length and two noncollagenous (NC) domains of variable sequence, size, and shape that are positioned at the N and C terminus.
- the collagenous domains contain the G-X-Y repeats and 0 form the typical triple helix within the collagen molecule while some of the NC domains form homo-trimers to stabilize the collagen triple helix.
- NC I extreme carboxy-terminal NC
- Fibril associated-collagens have recently been shown to trimerize via their NC2 domains (the second NC domain from the carboxy-terminal end) 15 16 .
- About 130 a.a. residues are present in 0 each monomer.
- the NCI domains from the multiplxin family members such as Collagen XV and XVIII formed the much smaller homo-trimer with the length of about 55 residues in each monomer 14 ' 20 .
- Both types of the collagen NC domains form very stable homo-trimers in solution (Tm>60°C) and are suitable as the scaffold protein as described in the invention.
- the Clq family is characterized by a C-terminal conserved globular Cl q domain (pfam ID: PF00386), which can form a stable homo-trimer 21"23 .
- the Cl q-like protein family includes, but not limited to, human C l q A chain, Cl q B chain, Clq C chain, cbln family members, human EMILIN-1 , multimerin, ACRP30/adiponectin, adipolin, resistin and resistin-like molecule (RELM) hormone family members.
- Tumor necrosis factor refers to a cytokine that can induce cell apoptosis and inflammation 24 ' 25 .
- TNF family (Pfam ID: PF00229) members include, but not limited, human TNFalpha, TNFbeta, TRAIL, RANK ligand, Fas ligand, CD 30 ligand, CD40 ligand, CD27 ligand, OX40L and CD137.
- TNF family members form homo-trimers in solution and demonstrated the similar molecular structure as the Clq family members. Therefore, these two family members are also named as Clq/TNF-related proteins (CTRP) 22 .
- CRP Clq/TNF-related proteins
- CTLDs C-type lectin-like domains
- PF00059 C-type lectin-like domains
- a number of CTLD proteins contain a neck and a C-terminal C-type carbohydrate-recognition domain (CRD) and they form homo-trimer in solution.
- CCD carbohydrate-recognition domain
- This type of CTLD includes mannan-binding lectin (MBL), surfactant protein A (SP-A), surfactant protein D (SP-D), collectin liver 1 (CL-L 1 ), collectin placenta 1 (CL-P 1 ), conglutinin, collectin of 43 kDa (CL-43) and collectin of 46 kDa (CL-46), Langerin and Tetranectin 27 ⁇ 30 .
- the CTRP family members including the Clq-like domains and TNF family members, have been utilized to fuse with the therapeutic polypeptide to extend the in vivo half life of the fusion protein.
- the CTLD family members can be employed as the scaffold protein to drive the trimerization of the therapeutic polypeptides.
- the NCI domain within Multiplexin type of human Collagen such as collagen XV and XVIII
- NC2 domain within FACIT type of collagen such as collagen IX, XII, XIV, XVI, XIX, XX, XXI, and XXII
- the therapeutic polypeptide 5 can be fused to either the N-terminus or the C-terminus of the scaffold protein.
- the trimer formation of the fusion protein can efficiently increase the radius of gyration (Rg) of the protein molecule.
- the fusion protein may demonstrate a much larger apparent size than a compact molecule with the same molecular weight. Therefore the fusion protein will show a much reduced clearing rate i o by renal filtration and will exhibit an extended half life in vivo.
- the term "scaffold protein” as used herein does not necessarily mean an entire wild type protein; a domain or functional variant thereof which can form a stable homo-trimer in solution and can therefore serve the purpose of the invention may also be used in our
- the C-terminal C lq-like domain of human ACRP30 and the neck and CRD domain of MBL were used as a scaffold protein.
- the therapeutic polypeptide may be selected from, but not limited to, human glucagon-like peptide- 1 (GLP-1), Calcitonin, human Parathyroid hormone (PTH), G-CSF, GM-CSF, Interferon, VEGF receptors, RANK, TNF receptors, growth hormone, Erythropoietin, single-chain Fv and single domain antibodies.
- GLP-1 human glucagon-like peptide- 1
- PTH human Parathyroid hormone
- G-CSF human Parathyroid hormone
- GM-CSF GM-CSF
- Interferon Interferon
- VEGF receptors vascular endothelial growth factor receptors
- RANK fibroblast growth factor receptors
- TNF receptors growth hormone
- Erythropoietin single-chain Fv and single domain antibodies.
- GLP-1 As one of the examples to illustrate how the method of the invention can significantly improve the pharmacokinetics property of GLP- 1 and its mutants while retaining its biological activity.
- the natural incretin hormone glucagon-like peptide- 1 (GLP-1) supports glucose homeostasis by enhancing glucose-dependent insulin secretion from ?-cells
- GLP-1 has been demonstrated to reduce appetite and food intake and inhibit gastric emptying, which may facilitate weight management ' . Therefore, GLP- 1 remains to be a very promising therapeutic polypeptide for type 2 diabetes and weight loss.
- GLP-1 is a 30 residue polypeptide with a very short half life in vivo, which severely limits its applications. In the present invention, we demonstrated data to show that the half life of GLP-1 can be significantly extended by use of the method of the invention.
- One advantage of the method is that it can render tri-valency for the therapeutic polypeptide. It has been well documented that multivalency of protein can greatly enhance its affinity and avidity to binding partner 33"35 .
- Antibody IgG is a Y-shaped molecule with bi-valency and utilizes two identical variable domains to interact with its ligand.
- the fusion protein generated using the method of the invention has tri-valency and therefore might behave better than the traditional human monoclonal antibody IgG in interacting with the ligand. For example, TNF alpha forms a homo-trimer in solution and interact with three TNF receptors simultaneously.
- TNF receptor 2 TNF receptor 2
- Enbrel Etanercept
- the scaffold protein utilized in this invention can form homo-trimers by simultaneous self assembly. No inter-chain disulfide bonds are needed to drive the trimerization.
- Many expression systems such as E. coli, yeast, insect cell and mammalian cell systems can be utilized to express the fusion proteins generated by the invention. In the sharp contrast, therapeutic monoclonal antibodies rely on the mammalian systems for mass productions.
- the therapeutic polypeptide and the scaffold protein are connected by a spacer.
- the spacer comprises a flexible un-structured linker whose length is adjustable.
- flexible un-structured linker refers to an amino acid sequence which is flexible in movement and which does not form any regular stable secondary and tertiary protein structures.
- the primary sequence of the "flexible un-structured linker” is usually rich in G, S, A, T or P.
- the therapeutic polypeptide is a relatively large protein (such as Interferon, Growth hormone, Erythropoietin, G-CSF, or TNFR2, usually a protein with more than 100 amino acid residues), it may be directly fused to the scaffold protein through a flexible, un-structured linker as the spacer (Fig. l ).
- the therapeutic polypeptide might be a short peptide (such as GLP- 1 or PTH, usually a peptide not more than 100 residues).
- the spacer between the therapeutic polypeptide and the scaffold protein may contain a proteinous connecting moiety, preferably a proteinous sequence with an elongated shape, such as the human Fibronectin type III domain.
- the proteinous connecting moiety can be connected to the therapeutic polypeptide and/or the scaffold protein via a flexible, un-structured linker.
- the proteinous connecting moiety can stabilize and elongate the spacer region within the fusion protein and further increase the radius of gyration (Rg) of the fusion protein.
- the proteinous connecting moiety contains a protein domain Fn8.
- the proteinous connecting moiety may comprise a whole protein, a truncated version of a protein, a protein domian or domains in tandem, or protein fragments.
- the proteinous connecting moiety may comprise some non-proteinous modifications which are not formed by amino acids, such as PEG.
- the length of the flexible, unstructured linker may play an important role in determining the radius of gyration (Rg) and the in vivo half life of the fusion protein.
- the flexible, unstructured linker may contain sequences such as (G4S)n, (G3S)n, (G2S2)n, where n is an integer, or other sequences that are rich in G, S, A, T or P.
- the length of the flexible linker may vary from 1 to 300 amino acid residues, and particularly within the range of 5 to 100 amino acid residues. It has been reported that the un-structured stretches of polypeptides may act like PEG molecule and increase the Rg of the protein molecule 36 . By use of our method, a shorter flexible linker is needed to reach the desired Rg due to the trimer formation compared with the monomer. This may have great advantages for therapeutic proteins by reducing the immunogenecity.
- the spacer may consist of one flexible, un-structured linker.
- the spacer may comprise a first flexible, un-structured linker, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), and a second flexible, un-structured linker.
- first flexible, un-structured linker and the second flexible, un-structured linker may be the same or different.
- the proteinous connecting moiety may comprise a whole protein, a single protein domain, or several protein domains in tandem which may be the same or different with each other.
- Fibronectin(Fn) is a high-molecular weight ( ⁇ 440kDa) glycoprotein of the extracellular matrix that binds to a number of proteins including integrins, collagen, fibrin and heparan sulfate proteoglycans (e.g. syndecans)
- Fibronectin exists as a protein dimer, consisting of two nearly identical polypeptide chains linked by a pair of C-terminal disulfide bonds.
- Each fibronectin monomer has a molecular weight of 230-250 kDa and contains three types domains: type I, II, and III. Type I and type II are stabilized by intra-chain disulfide bonds, while fibronectin type III domains do not contain 12 001723
- Fibronectin type III domain is an evolutionary conserved protein domain that is widely found in animal proteins.
- the human fibronectin protein in which this domain was first identified contains 16 copies of this domain (Fnl to Fnl 6).
- the fibronectin type III domain family (pfam ID: PF00041 ) member contains about 95 amino acids long and possesses a beta sandwich structure.
- Fibronection type III domain forms a very stable domain structure with the melting temperature of -70 °C as measured by DSC 39,4 °. Fibronectin type III domains are found in a wide variety of extracellular proteins.
- fibronection type III domain exists in many proteins including Tenascin, Usherin, Titin, tripartite motif (TRIM) family members, tissue factor, TIE1 , TIE2, SPEG, SORL1 , SDK1 , ROBOl , ROB02, SD 2, Receptor-type tyrosine-protein phosphatase, prolactin receptor, L I CAM, NCAM1 , NCAM2, myomesin 1 , myomesin 2, Myosin-binding protein C, LIFR, Leptin receptor, Integrin, Insulin receptor, Contactin, Collagen, Cytokine receptor-like factor, Inteferon receptor, Growth hormone receptor, fibronectin, leucine rich transmembrane protein (FLRT) members, IL, ephrin type-A receptor, ephrin type-B receptor, IL-6R, gpl30, IL1 1RA, IL 12RB, IL20RB, IL23R,
- Fibronectin type III domain as part of the spacer in our method may have low immunogenicity.
- the Fibronectin type III domains can also be used in tandem fashion in the spacer.
- Fibronectin type III domain can be expressed in recombinant form using a number of expression systems including E. coli, using Fibronectin type III domain as part of the spacer in the method of the invention may greatly increase the expression yield of the fusion protein.
- the present invention provides a novel technique termed as "Trident technology" which allows the therapeutic polypeptide to fuse with a scaffold protein which forms homo-trimer through a spacer with variable length.
- the trimer formation may greatly increase the Rg of the fusion molecule and improve the in vivo half life of the fusion protein.
- the scaffold proteins can be fused to the N-terminus or C-terminus of the therapeutic polypeptide.
- the length of the spacer between the therapeutic polypeptide and the scaffold protein can be modified to fine tune the pharmacokinetics feature of the fusion protein.
- the method of the invention can provide the therapeutic polypeptide with tri-valency, which may greatly increase the affinity and avidity of the fusion protein toward the ligand.
- the fusion protein can be further modified by PEGylation.
- the PEG moiety may have a molecular weight of between 2 and 100 kDa.
- the Cys residue may need to be generated in the fusion protein using site-directed mutagenesis.
- protein protein
- polypeptide peptide
- the term "functional variant" of a protein refers to a modified version of the native protein which comprises substitutions, deletions and/or additions of one or several amino acids, e.g., less than 15 amino acids, or preferably less than 10 or 5 amino acids, and which substantially retains the biological activity of the native protein. Typically, conservative substitutions of amino acids are preferred which are well known to a skilled artisan. Deletions are preferably deletions of amino acids from regions not involved in the biological function of the protein. For example, GLP-1 (A8G/G22E) is a functional variant of wild type GLP- 1 , which contains two substitutions of amino acids and which substantially retains its biological activity such as increasing cAMP level.
- the fusion proteins of the present invention can be produced through the application of recombinant DNA technology.
- Recombinant polynucleotide constructs encoding a fusion polypeptide of the present invention typically include an expression control sequence operably-linked to the coding sequences of the fusion polypeptide, including naturally-associated or heterologous promoter regions.
- another aspect of the invention includes vectors containing one or more nucleic acid sequences encoding a fusion polypeptide of the present invention.
- the nucleic acid containing all or a portion of the nucleotide sequence encoding the fusion polypeptide is inserted into an appropriate cloning vector, or an expression vector (i.e., a vector that contains the necessary elements for the transcription and translation of the inserted polypeptide coding sequence) by recombinant DNA techniques well s o known in the art and as detailed below. Methods for producing diverse populations of vectors have been described by Lerner et al., U.S. Pat. No. 6,291 , 160; 6,680,192.
- expression vectors useful in recombinant DNA techniques are often in the form of plasmids.
- expression vectors useful in recombinant DNA techniques are often in the form of plasmids.
- Plasmid and vector can be used interchangeably as plasmid is the most commonly used form of vector.
- the invention is intended to include such other forms of expression vectors that are not technically plasmids, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
- the 0 expression control sequences are eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences encoding the fusion polypeptide.
- expression vectors are typically 5 replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA.
- expression vectors contain selection markers, e.g. , ampicillin-resistance or kanamycin-resistance, to permit detection of those cells transformed with the desired DNA sequences.
- Vectors can also encode a signal peptide, e.g., pectate lyase, useful to direct the
- the recombinant expression vectors of the invention may comprise a nucleic acid encoding a fusion polypeptide in a form suitable for expression of 12 001723
- the recombinant expression vectors may include one or more regulatory sequences selected on the basis of the host cells to be used for expression that are operatively-linked to the nucleic acid sequence to be expressed.
- 5 "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g. , in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- regulatory sequence is intended to include promoters, enhancers and other
- expression control elements e.g. , polyadenylation signals.
- Such regulatory sequences are described, e.g. , in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. ( 1990).
- Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and
- fusion polypeptide-expressing host cells which contain a nucleic acid encoding one or more fusion polypeptides.
- the recombinant expression vectors of the invention can be designed for expression of a fusion polypeptide in prokaryotic or eukaryotic cells.
- a fusion polypeptide can be
- bacterial cells such as Escherichia coli, insect cells, fungal cells, e.g. , yeast, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 1 85, Academic Press, San Diego, Calif. (1990).
- the recombinant expression vector can be transcribed and
- vectors containing constitutive or inducible promoters directing the expression of the recombinant polypeptides may add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide.
- Such vectors with extra amino acid residues 5 typically serve three purposes: (i) to increase expression of recombinant polypeptide, (ii) to direct the recombinant protein to periplasmic space; and (iii) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification.
- Typical expression vectors serving this purpose include pGEX (GE Healthcare), pMAL (New England Biolabs), pET20b(Novagen),
- suitable inducible E. coli expression vectors include pTrc vectors (Invitrogen), pQE (Qiagen) and pET vectors (Novagen).
- pTrc vectors Invitrogen
- pQE Qiagen
- pET vectors Novagen.
- One strategy to maximize recombinant polypeptide expression is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the
- 1 5 individual codons for each amino acid are those preferentially utilized in the expression host, e.g., E. coli 41 .
- Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
- the fusion polypeptide expression vector is a yeast expression vector.
- yeast expression vectors for expression in yeast 0 Saccharomvces cerivisae include pYES2 (Invitrogen), pMFa 42 and pJRY88 43 .
- the fusion protein may also be expressed in Pichia system using the vectors pPICZ pGAPZ and pPIC9(InVitrogen).
- a fusion polypeptide can be expressed in insect cells using baculovirus expression vectors or using the stable insect cell lines.
- Baculovirus systems available for expression of 5 polypeptides in cultured insect cells ⁇ e.g. , SF9 cells include the BaculoGold system (BD Biosciences), BaculoDirect system (Invitrogen) and BacVector system (Novagen).
- the stable insect expression systems include, but not limited to, DES system (Invitrogen) and InsectDirect (Novagen).
- a nucleic acid encoding a fusion polypeptide of 0 the invention is expressed in mammalian cells using a mammalian expression vector.
- mammalian expression vectors include, e.g., but are not limited to, pcDNA3. 1 (Invitrogen), pSecTag (invitrogen), and pTriEx series vectors (Novagen).
- the expression vector's control functions are often provided by viral regulatory elements.
- commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40.
- the recombinant fusion protein can be expressed in the cytoplasm.
- the fusion protein can be secreted into the medium by adding an N-terminal secretion signal.
- host cell and "recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
- a host cell can be any prokaryotic or eukaryotic cell.
- a fusion polypeptide can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells. Mammalian cells are a preferred host for expressing nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes To Clones, (VCH Publishers, NY, 1987).
- a number of suitable host cell lines capable of secreting intact heterologous proteins have been developed in the art, and include Chinese hamster ovary (CHO) cell lines, 293 cells, various COS cell lines, HeLa cells, L cells and myeloma cell lines. Preferably, the cells are nonhuman.
- Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.
- Preferred expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papillomavirus, and the like.
- Other suitable host cells are known to those skilled in the art.
- a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
- selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate.
- Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding the fusion polypeptide or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. , cells that have incorporated the selectable marker gene will survive, while the other cells die).
- the fusion polypeptides are purified from culture media and/or host cells. Purification of recombinant polypeptides is well known in the art and includes ammonium sulfate precipitation, affinity chromatography purification technique, column chromatography, ion exchange purification technique, gel filtration and the like (see generally Scopes, Protein Purification (Springer- Verlag, N.Y., 1982).
- the present invention envisions treating a disease, for example, type II diabetes, in a mammal by the administration of the fusion protein compositions of the present invention.
- Administration of the fusion protein in accordance with the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
- the administration of the vaccines of the invention may be essentially continuous over a preselected period of time or may be in a series of spaced doses. Both local and systemic administration is contemplated.
- the pharmaceutical composition of the present invention may be delivered via various routes and to various sites in a mammal body to achieve a particular effect.
- routes e.g., a particular route can provide a more immediate and more effective reaction than another route.
- Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, peritoneal, subcutaneous, intradermal, as well as topical administration.
- the amount of the administered fusion protein of the present invention will vary depending on various factors including, but not limited to, the particular disease, the weight, the physical condition, and the age of the mammal, and whether prevention or treatment is to be achieved. Such factors can be readily determined by the clinician employing animal models or other test systems which are well known to the art.
- the amount of the fusion protein of the present invention to be administered to a mammal subject may vary in the range of l ng/kg to l OOmg/kg of the subject body weight. In an embodiment of the invention, the amount of administration was from 0.5mg/kg to l .Omg/kg.
- the fusion proteins of the invention are prepared for administration, they are preferably combined with a pharmaceutically acceptable carrier to form a pharmaceutical formulation, or unit dosage form.
- a pharmaceutically acceptable carrier commonly used pharmaceutically acceptable carriers are well known to a skilled artisan in the field of pharmacy.
- the total active ingredients in such formulations include from 0. 1 to 99.9% by weight of the formulation.
- the active ingredient for administration may be present as a powder or as granules; as a solution, a suspension or an emulsion.
- the therapeutic agent may be formulated for parenteral administration (e.g. , by injection, for example, bolus injection or continuous infusion) and may be presented in unit dosage form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative.
- the active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for re-constitution with a suitable vehicle, e.g. , sterile, pyrogen-free water, before use.
- water, suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
- Solutions for parenteral administration contain the active ingredient, suitable stabilizing agents and, if necessary, buffer substances.
- Antioxidizing agents such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, are suitable stabilizing agents.
- parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl -paraben and chlorobutanol.
- Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field
- control release preparations can include appropriate macromolecules, for example polymers, polyesters, polyamino acids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate.
- concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release.
- the agent can be incorporated into particles of polymeric materials such as polyesters, polyamino acids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.
- compositions, carriers, and reagents are used interchangeably and represent that the materials are capable of administration to or upon a subject without the production of undesirable physiological effects to a degree that would prohibit administration of the composition.
- Such carriers include, but are not limited to, water, saline, Ringer's solutions, and dextrose solution. Liposomes and non-aqueous vehicles such as fixed oils may also be used.
- the use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the fusion polypeptides, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- the fusion polypeptides compositions of the present invention can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intradermal, transdermal, rectal, intracranial, intraperitoneal, intranasal; intramuscular route or as inhalants.
- the fusion polypeptides can optionally be administered in combination with other agents that are at least partly effective in treating various diseases including various actin- or microfilament-related diseases.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, e.g. , by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, e.g. , parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic compounds e.g. , sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, e.g. , aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the fusion polypeptides in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the binding agent into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- methods of preparation are vacuum drying and freeze-drying that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the agents of this invention can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets.
- the binding agent can be incorporated with excipients and used in the form of tablets, troches, or capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
- Pharmaceutically compatible binding compounds, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin, an excipient such as starch or lactose, a disintegrating compound such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening compound such as sucrose or saccharin; or a flavoring compound such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose
- a disintegrating compound such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the fusion polypeptides are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, e.g. , for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the fusion polypeptides are formulated into ointments, salves, gels, or creams as generally known in the art.
- the fusion polypeptides can also be prepared as pharmaceutical compositions in the form of suppositories (e.g., with conventional suppository 5 bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository 5 bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- Example 1 Construction of an expression vector of GLP-1 fused with human Fibronectin type III domain 7 (Fn7) and human collagen XVIII NC I domain (COL 1 8NC 1 )
- GLP- 1 polypeptide was fused to the N-terminus of i s the human collagen XVIII NC I domain (COL1 8NC 1 ) which forms a stable homo-trimer.
- the human Fibronectin type III domain 7 was connected to the GLP-1 polypeptide and COL1 8NC 1 through two flexible, unstructured linkers 1 and 2 (linker 1 : GGGSGGGG, linker 2: GGGSGG).
- ?.o Novagen was used to construct a recombinant plasmid containing the GLP- 1 -Fn7-C0L 1 8NC1 fusion gene.
- human COL 1 8NC 1 was cloned into pET29b by BamHl and Xho ⁇ to result in the pET29b-COL 1 8NC l vector.
- PCR reaction was carried out using human collagen XVIII cDNA as the template by using the following primers:
- PCR product was digested by restrictive enzyme B mHl and Xhol 30 (Fermentas) and ligated into the pET29b vector by use of T4 ligase (Fermentas).
- T4 ligase Framentas
- the sequence of resulted pET29b-COL18NCl vector was confirmed by DNA sequencing.
- PCR reaction was carried out using human Fibronectin cDNA as the template by using the following primers:
- GLP- 1 -Fn7-C0L18NC 1 protein sequence Fn7 is connected to GLP-1 and COL18NC1 by use of two flexible unstructured linkers 1 and 2.
- the flexible, unstructured linker 1 between GLP- 1 and Fn7 (GGGSGGGG) is underlined.
- the flexible, unstructured linker 2 (GGGSGG) between Fn7 and COL18NC1 is also underlined.
- GLP-1 sequence is in italic.
- Fibronectin type III domain 8 Fn8
- the gene encoding human Fibronectin type III domain 8 (Fn8) was amplified by PCR using the following primers and human Fibronectin cDNA as the template:
- the PCR product was digested by Ndel and BamHl.
- the digested insert was ligated into the digested vector pET29b-COL1 8NC l (generated in example 1 ).
- the resulted vector was named as pET29b-GLP- l -Fn8-COL 1 8NC l .
- the protein sequence of the fusion protein GLP- l -Fn8-COLl 8NC 1 was listed as SEQ ID NO: 2.
- GLP-1 -Fn8-C0L18NC1 protein sequence GLP-1 sequence is in italic.
- Fn8 is connected to GLP- 1 and COL 18NC 1 by use of two flexible unstructured linkers 1 and 2.
- the flexible, unstructured linker 1 between GLP- 1 and Fn8 (GGGSGGGGS) is underlined.
- the flexible, unstructured linker 2 (GGGSGG) between Fn8 and COL18NC1 is also underlined.
- the constructed expression vector pET29b-Glpl -Fn8-COL1 8NC l was used to transform Escherichia coli BL2 1 (DE3) for protein expression (for detailed protocols of the transformation, see Molecular Coining: A Laboratory Manual).
- a single colony was selected from the culture dish, and placed into a 10 ml LB liquid medium with kanamycin (final concentration, 50 ⁇ g/ml), then shaken at 37 °C at 220 rpm overnight.
- 1 L LB culture was inoculated and allowed to grown until OD 6 oo reached 0.4- 1.0.
- Isopropyl thiogalactoside (1PTG) was added to a final concentration of 0.2mM.
- the proteins of interest were present in the supernatant, with the expressed product comprising 20% of soluble proteins. 50ml of the supernatant was loaded on a HiTrap Q column (5ml) (GE healthcare). The fusion protein of GLP1 -Fn8-C0L 1 8NC 1 was eluted with about 0.3 M NaCl in the buffer. ! 0 The eluted protein was further purified by gel filtration column S-200 (GE Healthcare), and the buffer was replaced with PBS (pH 7.5). The final product was confirmed by SDS-PAGE electrophoresis.
- A8G/G22E/R36S within the Glp- 1 sequence may increase its resistance to protease digestion, reduce immunogenicity and boost its biological activity ' 44 .
- the 0 PCR reaction was carried out using vector pET29b-GLP 1 -Fn8-COL 1 8NC 1 prepared in example 2 as the template with the following primers:
- the PCR product was digested by Nde ⁇ and Xhol (Fermentas).
- the digested insert was ligated into the digested vector of pET29b.
- the resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NC l . ⁇ ⁇
- GLP- 1 (A8G/G22E)-Fn8-C0L 1 5NC 1 was the same as described in example 3.
- Other mutations, such as A8V/G22E, A8S/G22E and A8G/G22E/R36S, within the GLP- 1 can be generated using the Quikchange II site-directed mutagenesis kit (Agilent) using the GLP- 1 (A8G/G22E)-Fn8-C0L 1 5NC 1 gene as the template.
- the protein sequences of these GLP l mutants fused with Fn8-C0L 1 8NC 1 were listed as SEQ ID NO. 3-6.
- the expression and purification protocol of these fusion proteins can be carried out using similar protocols described in example 3.
- GLP- 1 (A8G/G22E)-Fn8-C0L18NC 1 protein sequence, the GLP-1 mutation sites
- HGEGTFTSDVSSYLEEQAAKEFIAWLV G GGGGSGGGGSAVPPPTDLRFTNIGPDT RVTWAPPPSIDLTNFLVRYSPVK NKEDVAELSISPSDNAVVLT LLPGTEYVVSVSSVYEQHESTPLRGRQKTG
- GLP- 1 (A8V/G22E)-Fn8-C0L18NC1 protein sequence, the GLP-1 mutation sites
- GLP-l (A8G/G22E/R36S)-Fn8-C0L18NCl protein sequence, the GLP-1 mutation sites
- the fibronectin type III domain that can be used as part of the spacer for our method is not limited within human fibronectin.
- Other suitable fibronectin type III domain may alternatively be utilized in the spacer in the method of the invention.
- a fibronectin type III domain from human Tenascin C can be utilized as part of the spacer between the therapeutic polypeptide and the scaffold protein as well.
- the human Tenascin C fibronectin type III domain 3 (TNCfn3) was connected to the GLP- 1 polypeptide and COL1 8NC 1 through two flexible, unstructured linkers 1 and 2 (linker 1 : GGGSGGGGS, linker 2: GGGSGG).
- the gene encoding TNCfn3 was amplified by PCR using human Tenascin C cDNA as template using the following primers : TNCfn3-Forward.
- the PCR product was digested by Ndel and BamUl (Fermentas).
- the digested insert was ligated into the digested vector pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NC l as prepared in example 4.
- the resulted vector was named as pET29b-GLP l (A8G/G22E)-TNCfn3-COL 1 8NC l .
- the expression and purification protocol of the fusion protein GLP l (A8G/G22E)-TNCfn3-COL 18NC l (SEQ ID NO:7) was the same as described in example 3.
- TNCfn3 is connected to GLP-1 and COL18NC1 by use of two flexible unstructured linkers 1 and 2.
- the flexible, ! unstructured linker 1 between GLP-1 and TNCfn3 (GGGSGGGGS) is underlined.
- the flexible, unstructured linker 2 (GGGSGG) between TNCfn3 and COL18NC 1 is also underlined.
- the PCR product was digested by restrictive enzyme BamWl and Xhol
- the expression and purification protocol of the fusion protein GLP 1 (A8G/G22E)-Fn8-C0L1 5NC 1 (SEQ ID NO: 8) was the same as described in example 3.
- SEQ ID NO: 8 GLP- 1 (A8G/G22E)-Fn8-C0L15NC 1 protein sequence, the sequence of COL15NC1 is underlined.
- the flexible unstructured linker 1 (GGGSGGGGS) between GLP- 1 and Fn8 is in italic.
- the flexible unstructured linker 2 (GGGSGG) between Fn8 and COL15NC1 is also in italic.
- HGEGTFTSDVSSYLEEQAAI EFIAWLVKGRGGGG5GGGG5AVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK NEEDVAELSISPSDNAVVLT LLPGTEYVVSVSSVYEQHESTPLRGRQ TG
- XIX can be utilized as the scaffold protein in our method. It has been shown that human collagen XIX NC2 domain (COL 19NC2) forms a highly stable homo-trimer 16 .
- PCR reaction was carried out using human collagen XIX cDNA as the template by using the following primers:
- the PCR product was digested by restrictive enzyme BamUl and Xho ⁇ (Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NC l vector as prepared in example 4 by use of T4 ligase (Fermentas).
- the resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-COL19NC2 and the sequence of the vector was confirmed by DNA sequencing.
- the protein sequence of GLP l (A8G/G22E)-Fn8-COL 19NC2 was listed as SEQ ID NO:9.
- the expression and purification protocol of the fusion protein GLP l (A8G/G22E)-Fn8-COL 19NC2 was similar as that was described in example 3.
- SEQ ID NO: 9 GLP-l (A8G/G22E)-Fn8-COL19NC2 protein sequence, the sequence of COL19NC2 is underlined.
- the flexible unstructured linker 1 (GGGSGGGGS) between GLP- 1 and Fn8 is in Italic.
- the flexible unstructured linker 2 (GGGSGG) between Fn8 and COL19NC2 is also in italic.
- HGEGTFTSDVSSYLEEQAA EFIAWLVKGRGGGGSGGGG5AVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK NF.F.DVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG
- ACRP30 (also referred to as Adiponectin, GBP-28, apMl and AdipoQ) is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism 45 .
- ACRP30 contains a C-terminal globular domain that forms a homo-trimer with typical Clq-like structure 46 .
- Cl q-like domain such as the ACRP30 C l q-like domain, can be utilized as the scaffold protein in our method.
- the PCR product was digested by restrictive enzyme BamHl and Xhol (Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NCl vector as prepared in example 4 by use of T4 ligase (Fermentas).
- the resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-ACRP30 and the sequence of the vector was confirmed by DNA sequencing.
- the protein sequence of GLP 1 (A8G/G22E)-Fn8-ACRP30 was listed as SEQ ID NO: 10.
- the expression and purification protocol of the fusion protein GLP 1 (A8G/G22E)-Fn8-ACRP30 is similar as described in example 3.
- GLP- 1(A8G/G22E)-Fn8-ACRP30 protein sequence the sequence of ACRP30 Cl q-like domain is underlined.
- the flexible unstructured linker 1 (GGGSGGGGS) between GLP-1 and Fn8 is in italic.
- the flexible unstructured linker 2 (GGGSGG) between Fn8 and ACRP30 is also in italic.
- HGEGTFTSDVSSYLEEQAA EFIAWLVKGRGGGG5GGGGSAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK
- Example 9 Cloning and expression of GLP- 1 (A8G/G22E) fused with Fn8 and human mannose-binding lectin ( BL) neck and CRD domain.
- MBL Human mannose-binding lectin
- CTL C-type lectin-like domain
- CRD C-terminal carbohydrate recognition domain
- PCR reaction was carried out using human MBL cDNA as the template by using the following primers:
- the PCR product was digested by restrictive enzyme BamHl and Xhol (Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL1 8NC l vector as prepared in example 4 by use of T4 ligase (Fermentas).
- the resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-MBL and the sequence of the vector was confirmed by DNA sequencing.
- the protein sequence of GLP 1 (A8G/G22E)-Fn8-MBL was listed as SEQ ID NO: 1 1.
- the expression and purification protocol of the fusion protein GLP 1 (A8G/G22E)-Fn8-MBL (SEQ ID NO: 1 1 ) was similar as described in example 3.
- SEQ ID NO: 1 1 GLP-1(A8G/G22E)-Fn8-MBL protein sequence, the sequence of the neck and CRD domain of MBL is underlined.
- the flexible unstructured linker 1 (GGGSGGGGS) between GLP-1 and Fn8 is in italic.
- the flexible unstructured linker 2 between Fn8 and MBL is italicized.
- Example 10 Between the therapeutic polypeptides and the scaffold proteins, various spacer lengths can be used to generate the fusion proteins with the desired radius of gyration (Rg)
- the flexible unstructured linker 2 between Fn8 and COLl 8NC 1 contains six residues (GGGSGG).
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -20
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
- GLP- 1 A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and GLP- l (A8G/G22E/R36S)-Fn8-COL18NCl -60.
- the length of the flexible linker 2 between Fn8 and COL18NC1 contained 20, 30, 54 and 60 residues, respectively.
- GLP- 1 (A8G/G22E/R36S)-Fn8-COLl 8NC1-20
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
- GLP-l (A8G/G22E/R36S)-Fn8-COL 18NCl -60 are listed as SEQ ID NO:
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -20
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
- GLP- 1 A8G/G22E/R36S-Fn8-COL 18NC 1 -60 were grafted to the pET29b by Ndel and Xho ⁇ for protein expressions. The expression and purification of these fusion proteins were carried out using similar protocols described in
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC1 ,
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC1 -20
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC1 -30
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
- GLP-l(A8G/G22E/R36S)-Fn8-COL18NCl trimer exhibited an apparent molecular weight of ⁇ 100Kd while its genuine molecular weight is ⁇ 68Kd.
- GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl-20, GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -30 exhibited larger apparent molecular weight than their genuine molecular weight as well. Therefore, our method can provide the therapeutic polypeptide with a larger Rg which exhibited increased apparent molecular size on gel filtration profile for longer in vivo half life.
- the flexible linker between the therapeutic polypeptide and the scaffold protein may adjust the Rg of the fusion molecule in a tunable manner.
- SEQ ID NO: 14 protein sequence of GLP- l(A8G/G22E R36S)-Fn8-COL18NCl-54, the flexible unstructured linker 2 (54 residues) between Fn8 and COL18NC1 is underlined.
- the flexible unstructured linker I between GLP- 1 and Fn8 (GGGSGG) is also underlined.
- HGEGTFTSDVSS YLEEOAAKEFIAWLV GSGGGGSGGAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKN EEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG GGGGSGGGGSTASSASTGGPSGGGGSGGGGSAPSSGSTSGGTAAGGGGSGGGGS GASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFR VQLEARTPLPRG 01723
- SEQ ID NO: 21 protein sequence of GLP- l (A8G/G22E/R36S)-Fn8-COL18NC l-60, the flexible unstructured linker 2 (60 residues) between Fn8 and COL18NC1 is underlined.
- the flexible unstructured linker 1 between GLP-1 and Fn8 (GGGSGG) is also underlined.
- GLP-1 Through binding and activating a specific G protein-coupled receptor (GLP- 1 receptor), GLP-1 stimulates the signaling pathway to increase cAMP 5 level in cells. Therefore, measuring the cytoplasmic cAMP level can be an accurate method to evaluate the biological activity of GLP-1.
- Chinese Hamster Ovary (CHO) cells stably transfected with human GLP- 1 receptor (GLP- 1 R) were generated and named as S-CHO cells. S-CHO cells were propagated in D EM medium with 10% FCS containing 0.05mg/ml G418. Before analysis, s o SCHO cells were grown to 70-80% confluence in 6-well plates at 37°C. The cells were treated 0.2mM 3-isobutyl-l -methylxanthine (IBMX).
- IBMX 3-isobutyl-l -methylxanthine
- the Parameter cAMP ELISA kit from R&D Systems was utilized to measure the cAMP concentrations in the cell lysates.
- the EC50 values of the GLP-1 fusion proteins were generated by using the software Origin.
- the GLP- 1 (7-37) peptide (Anaspec) and BSA were used as positive and negative controls.
- Fig. 4 showed the results of cAMP assays for GLP 1 0 (7-37) peptide, GLP1 (A8G/G22E)-Fn8-C0L18NC 1 fusion protein and GLP l (A8G/G22E)-Fn8-COL 18NCl-54 fusion protein.
- Example 12 The pharmacokinetics studies for GLP- 1 (A8G/G22E/R36S)-Fn8-COL 1 8NC 1 ,
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -20
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -30
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
- GLP- 1 (A8G/G22E/R36S)-Fn8-COL18NC 1-54 in PBS buffer, pH 7.2.
- These fusion proteins were administered on SD(Sprague-Dawley) rats by intraperitoneal injections at the concentration of 0.66mg, 0.72mg, 0.75mg,0.78mg/kg animal respectively.
- Blood samples were taken at various time points after injections such as 0-min, 30-min, 1 -hour, 2-hour, 4-hour, 8-hour, 24-hour, 48-hour, 3-day, 4-day, 5-day. 7-day, 10-day..
- the serum samples were centrifuged and kept at -80°C freezer.
- the GLP-1 concentrations within the samples were examined by use of the sandwich ELISA method.
- the mouse monoclonal antibody against GLP- 1 peptide at the concentration of lug/ml (sc57510, Santa Cruz Biotech) was coated on ELISA plate for 1 hour at room temperature. Then the plate was washed by PBST buffer three times and the wells were blocked by PBS with 10% FBS for 1 hour at room temperature. The plate was washed three times before the serum samples containing GLP-1 fusion proteins were added. The serum samples could be diluted to 20-50 folds before use. The ELISA plate was incubated with the serum samples at room temperature for 1 hour and then washed by PBST buffer five times.
- Fibronectin rabbit ploy clonal antibody (Abeam, ab299) at the concentration of lug/ml in PBST buffer was added to the wells. The plate was washed extensively after incubation of 1 hour at room temperature.
- the secondary antibody Goat anti-rabbit IgG HRP conjugated antibody (Beijing ZSGB-Bio company, ZB 5301 ), was added into the wells and the color was developed using TMB (3,3 ⁇ 5,5'-tetramethylbenzidine, BD biosciences, Cat 555214 ).
- the plate reader Bio -Rad microplate reader Model 680 was utilized to obtain the OD450 readings. This method has been calibrated using purified proteins first.
- Fig. 5 showed the pharmacokinetics profiles of the GLP-1 containing proteins by use of the sandwich ELISA method described above.
- the pharmacokinetics parameters were obtained by using the WinNonlin software (Table 2).
- Table 2 The data clearly showed that the GLP- 1 containing fusion proteins generated by use of the method of the invention exhibited much extended in vivo half life possibly due to their enlarged Rg.
- the data also showed that the flexible, unstructured linker between the therapeutic polypeptide and the scaffold protein may adjust the in vivo half life of the fusion molecules in a tunable manner.
- GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
- GLP-l(A8G/G22E/R36S)-Fn8-COL18NCl-54 were shown in abbreviation as NCl,NCl-20,NCl-30,NCl-54.
- PTH Human parathyroid hormone
- PTH(l-34) and PTH(l-84) in circulation is quite short, which limits their applications 49 .
- we applied the method of the invention on human PTH(l-34) and PTH(l-84) by fusing human PTH(l-34) and PTH(l-84) with human collagen XVIII NCI (COL18NC1).
- the synthetic genes encoding human PTH(l-34) and PTH(l-84) were digested by Ndel and BamWl and ligated into the digested vector pET29b- COL18NC1 (generated in example
- PTH-COL18NC1 The protein sequences of PTH(l-34)-COLl 8NC1 and PTH-COL1 8NC 1 are listed as SEQ ID NO: 15 and 16.
- the recombinant PTH( l -34)-COL1 8NC l and PTH-COL 18NC 1 have been prepared and the purities of the proteins were examined by SDS-PAGE analysis (purity>95%). The biological acitivities of these proteins were measured by use of the cAMP assay.
- PTH can interact with the PTH receptor to stimulate the cAMP production.
- the cAMP assay was carried out as described in example 1 1 except that the rat osteosarcoma cell line UMR- 106 (ATCC) was utilized in the assay.
- Calcitonin inhibits bone removal by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass It has been shown that Salmon calcitonin is more effective than human calcitonin.
- the Salmon calcitonin (sCT) is currently used in the treatment of osteoporosis.
- the half life of calcitonin in human circulation is short (-50 minutes), which limits its applications.
- the synthetic gene encoding salmon calcitonin was digested by Ndel and BamHl and ligated into the digested vector pET29b- COL1 8NC 1 (generated in example 1 ) to construct the fusion gene sCT-COL 18NC l .
- the protein sequence of sCT-COLl 8NC 1 was listed as SEQ ID NO: 17.
- Example 1 5 Construction of the fusion protein of TNFR2 and COL 1 8NC1 TNF Receptor (TNFR2, or p75) has been fused to IgG l Fc fragment to constitute a fusion protein Etanercept (Enbrel). Etanercept has been successfully utilized to treat severe active rheumatoid arthritis by blocking the TNF alpha functions 50 .
- Etanercept has been successfully utilized to treat severe active rheumatoid arthritis by blocking the TNF alpha functions 50 .
- TNFR2-COL 1 8NC 1 fusion protein is tri-valent and can block all three binding sites of TNFalpha while retaining a long half life in vivo.
- Etanercept molecule can only block two out of three possible binding sites located on TNF alpha homo-trimer.
- a flexible unstructured linker of 60 residues was utilized to connect TNFR2 and COL 18NC1 in the fusion protein.
- the gene that encoded the protein sequence ID: 18 was synthesized and sub-cloned into pET29b by Ndel and Xhol. SEQ ID NO: 18.
- the flexible unstructured linker between TNFR2 and COL18NC 1 is underlined.
- TNFR2-COL1 8NC 1 The protein expression of TNFR2-COL1 8NC 1 was carried out as described in example 3. Most of the fusion protein TNFR2-COL1 8NC 1 was expressed as the inclusion bodies. The inclusion bodies were washed extensively by use of 50mM Tris buffer (pH8.0), NaCl 150mM, EDTA 5mM, Tween20 0. 1 %. The inclusion bodies were dissolved in 50mM Tris buffer (pH8.0), Urea 8M, DTT 50mM, NaCl 150mM. The denatured protein was cleared by high speed centrifugation (1 5,000g) for 15 minutes and the protein concentration was adjusted to 0.5mg/ml.
- the protein refolding was carried out by dialysis against 50mM Tris buffer (pH 8.5), NaCl 1 50mM, I mM EDTA, 2mM Cystine, PEG3350 0. 1 %, L-Arginine 50mM and Tween20 0.05%. The refolding was allowed at 4°C for three days.
- the refolded TNFR2-COL 1 8NC 1 fusion protein was further purified by use of Hitrap SP HP column and gel filtration column Superdex 200 (GE Healthcare). The purified protein was kept in 20mM Hepes buffer (pH 7.5), NaCl 1 50mM. The purity of the fusion protein was examined by SDS-PAGE electrophoresis (purity >95%).
- TNFR2-COL 1 8NC 1 The biological activity of TNFR2-COL 1 8NC 1 was measured by its ability to block the TNFalpha signaling. Our data indicated that TNFR2-COL 1 8NC 1 can inhibit the cell killing activity of TNFalpha for L929 cells as efficiently as TNFR2-IgG l Fc fusion protein.
- Example 16 Construction of the fusion protein VEGFRl R2 and COL 1 8NC 1
- VEGF Vascular endothelial growth factor
- VEGFR l R2 we applied the method of the invention to VEGFR l R2 to generate a tri-valent VEGFR 1 R2-COL 1 8NC 1 fusion protein.
- a flexible unstructured linker of 60 residues was utilized to connect the VEGFR 1 R2 and COL 1 8NC 1 in the construct.
- VEGFR 1 R2-COL 1 8NC I The synthetic gene that encodes the human VEGFR 1 R2-COL 1 8NC I was grafted into the digested vector pET29b by use of Ndel and Xhol.
- the protein sequence of VEGFR1 R2-COL1 8NC 1 fusion protein was listed as SEQ ID NO: 19.
- VEGFR 1 R2-COL 1 8NC 1 The expression and refolding of VEGFR 1 R2-COL 1 8NC 1 was carried out using the similar protocol as described in example 15. The purity of the fusion protein was examined by SDS-PAGE electrophoresis (purity >95%). The biological activity of VEGFR 1 R2-COL 1 8NC1 fusion protein was shown by its ability to interact with VEGF. Our data from SPR by use of Biacore indicated that VEGFR 1 R2-COL 1 8NC1 fusion protein can bind VEGF with the similar affinity as the VEGFR l R2-IgG Fc fusion protein. SEQ ID NO: 19, VEGFR1 R2-COL18NC 1 fusion protein sequence. The flexible unstructured linker region between VEGFR1 R2 and COL18NC1 is underlined.
- Example 17 Construction of the fusion protein of human RANK and COL1 8NC 1
- RANK Ligand In many bone loss conditions, RANK Ligand (RANKL) overwhelms the body's natural defenses against bone destruction 52 . Therefore, blocking the RANKL functions has been utilized to treat osteoporosis.
- the monoclonal antibody Denosumab is designed to target RANKL, and it has been approved by FDA to treat osteoporosis. It has been shown that RANK extra-cellular domain can interact with RANKL with high affinity (Kd ⁇ 60pM) ⁇ RNAKL forms a homo-trimer in solution and RANK extra-cellular domain forms a monomer.
- RANK was clustered into a homo-tnmer by use of the method of the invention to interact with RANKL.
- a flexible unstructured linker of 60 residues was utilized to connect RANK extra-cellular domain with COL 18NC1 in this example.
- the RANK-COL 18NC1 fusion gene was synthesized and sub-cloned into pET29b for expression.
- the protein sequence of RANK-COL 1 8NC 1 fusion protein was listed as SEQ ID NO: 20.
- RANK-COL 1 8NC 1 The expression and refolding of RANK-COL 1 8NC 1 was carried out using the similar protocol as described in example 15.
- the purity of the fusion protein was examined by SDS-PAGE electrophoresis (purity >95%).
- the biological activity of RANK-COL 1 8NC 1 fusion protein was shown by its ability to interact with RANK ligand.
- MF alpha a putative alpha-factor precursor contains four tandem copies of
- Burcelin, R. et al. Encapsulated, genetically engineered cells, 0 secreting glucagon-like peptide- 1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N YAcad Sci 875, 277-85 ( 1999).
Abstract
A fusion protein comprises of a therapeutic polypeptide and a scaffold protein. The therapeutic polypeptide and the scaffold protein could be connected by a spacer polypeptide. The scaffold protein forms a stable trimeric structure in solution. Also provided are nucleic acids, vectors, pharmaceutical compositions and methods of improving the pharmacokinetic property.
Description
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
Field of the Invention
The present invention relates generally to a fusion protein with therapeutic efficacy. In particular, the present invention relates to a method of improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer.
Background of the Invention
Most human proteins, except antibodies and human serum albumin (HSA), are quickly cleared from human circulation. Short plasma half life times are commonly due to fast renal clearance as well as to enzymatic degradation occurring during systemic circulation. Many therapeutic polypeptides require long half life time to achieve their optimal efficacy. Increasing the in vivo residence times of therapeutic polypeptides could decrease their dosing frequencies.
PEGylation has been widely utilized to extend the half life of a therapeutic polypeptide (see review paper , patents 1-9). PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug. In general, PEGylation improves drug solubility and decreases immunogenicity. PEGylation also increases drug stability and the retention time of the conjugates in blood. However, PEGylation has severe consequences for the biological activities of the protein. The activity of the PEGylated protein usually reduces by 20-50 fold 2'5(patents 1 -9). In addition, the site for PEGylation needs to be carefully decided to avoid interfering with the active site of the therapeutic polypeptide. For some short peptides such as GLP- 1 , PTH and Calcitonin, it would be difficult to choose the proper site for PEGylation without disturbing the biological activity of the peptides.
It has been reported that fusion of a therapeutic polypeptide with human
IgG Fc fragment or human serum albumin (HSA) may significantly increase the half life of the therapeutic polypeptide 6 9 (patents 10, 1 1 , 12). However, recombinant fusion protein with IgG Fc fragment or HSA needs to be produced from eukaryotic systems such as mammalian cell lines or yeast cells, which significantly increases the cost of the recombinant protein.
Summary of the invention
In one aspect, the present invention provides a fusion protein comprising a therapeutic polypeptide fused to a scaffold protein which forms a homo-trimer in solution, wherein the therapeutic polypeptide is connected with the scaffold protein via a spacer, and the spacer comprises a flexible un-structured linker whose length is adjustable.
In some embodiments, the spacer further comprises a proteinous connecting moiety. In a particular embodiment, the proteinous connecting moiety is a proteinous sequence having an elongated shape, such as human Fibronectin type III domain. In some embodiments, the proteinous connecting moiety is connected with the therapeutic polypeptide and/or the scaffold protein via a flexible un-structured linker.
In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a first flexible un-structured linker (linker 1), a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), a second flexible un-structured linker (linker 2), and the scaffold protein. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), the flexible un-structured linker, and the scaffold protein. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the therapeutic polypeptide, the flexible un-structured linker, and the scaffold protein. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the scaffold protein, a first flexible un-structured linker, a proteinous connecting moiety (preferably a proteinous sequence with an
elongated shape), a second flexible un-structured linker, and the therapeutic polypeptide. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the scaffold protein, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), the flexible un-structured linker, and the therapeutic polypeptide. In some embodiments, the fusion protein of the invention comprises, from N-terminus to C-terminus, the scaffold protein, the flexible un-structured linker, and the therapeutic polypeptide.
In some embodiments, the scaffold protein of the invention is selected from the group consisting of human collagen noncollagenous (NC) domains which form stable homo-trimers in solution, proteins which form homo-trimers in solution with C l q-like molecular structures, proteins which form homo-trimers in solution with TNF-like molecular structures, and proteins with C-type lectin-like domains (CTLD) which form homo-trimers in solution.
In some embodiments, the therapeutic polypeptide is selected from the group consisting of human glucagon-like peptide- 1 (GLP-1 ), Calcitonin, human Parathyroid hormone (PTH), G-CSF, GM-CSF, Interferon, VEGF receptors, TNF alpha receptors, RANK, Growth hormone, Erythropoietin, single-chain Fv, single domain antibodies and functional variants thereof.
In particular embodiments of the invention, the fusion protein of the invention comprises: a therapeutic polypeptide selected from the group consisting of GLP- 1 , GLP 1 (A8G/G22E) and GLP 1(A8G/G22E R36S); a first flexible un-structured linker; a proteinous connecting moiety selected from the group consisting of Fn7, Fn8 and TNCfn3, a second flexible un-structured linker; and a scaffold protein selected from the group consisting of COL 18NC1 , COL15NC1 , COL19NC2, ACRP30 C l q-like domain, and MBL neck and CRD domain.
In a preferred embodiment of the invention, the fusion protein of the invention comprises: GLP 1 (A8G/G22E/R36S), a first flexible un-structured linker, Fn8, a second flexible un-structured linker, and COL18NC1.
The present invention also provides a polynucleotide sequence encoding
the fusion protein, a pharmaceutical composition comprising the fusion protein and a pharmaceutically acceptable carrier, and an expression vector comprising the polynucleotide sequence and expression control elements.
In another aspect, the present invention provides a method of improving the pharmacokinetic property of a therapeutic polypeptide, comprising the step of fusing the therapeutic polypeptide to a scaffold protein which forms a homo-trimer in solution, wherein the therapeutic polypeptide is connected with the scaffold protein via a spacer, and the spacer comprises a flexible un-structured linker whose length is adjustable to adjust the apparent molecular size and/or the in vivo half life of the fusion protein.
Brief Description of the Drawings
Fig. 1 shows the schematic drawings illustrating the mechanisms of the present invention. The therapeutic polypeptide is shown as a red star in Fig. l a and as a red helix in Fig. lb, the spacer is shown in blue and the scaffold protein is shown as a grey sphere, a) The therapeutic polypeptide can be connected to the scaffold protein by a flexible, unstructured linker as the spacer, b) The therapeutic polypeptide can be connected to the scaffold protein by a first flexible unstructured linker (linker 1 ), a proteinous connecting moiety (preferably with an elongated shape, such as Fibronectin type III domain) and a second flexible unstructured linker (linker 2) as the spacer.
Fig. 2 shows the result of SDS-PAGE analysis of purified proteins.
GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl ,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -20,
GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl-30,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
GLP- l (A8G/G22E/R36S)-Fn8-COL18NCl-60 are shown in lane 1 , 2, 3, 4 and 5. The molecular markers are labeled at the left of the 12% gel.
Fig. 3 shows the gel filtration chromatography profiles for purified GLP-1 (A8G/G22E/R36S)-Fn8-COLl 8NC1 ,
G LP- 1 ( A8G/G22E/R36S)-Fn8-COLl 8NC 1 -20,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -60 using the analytical column Superdex200 (GE Healthcare). In this figure, the profiles of these proteins are labeled as NCI , NCI -20, NCI -30, NCI -54 and NCI -60. The elution time for the molecular marker proteins (158Kd and 44Kd) are shown by arrows. The X-axis refers to elution time and the Y-axis refers to UV280 absorbance intensity.
Fig. 4 shows the results of cAMP assays for GLP- 1 (7-37) peptide, GLP l (A8G/G22E/R36S)-Fn8-NCl and
GLPl(A8G/G22E/R36S)-Fn8-NCl -54. This assay is based on competitive binding technique. A monoclonal antibody specific for cAMP becomes bound to the goat anti-mouse antibody coated onto the microplate. Following a wash to remove excess monoclonal antibody, cAMP present in a sample competes with a fixed amount of horseradish peroxidase (HRP)-Iabeled cAMP for sites on the monoclonal antibody. This is followed by another wash to remove excess conjugate and unbound sample. A substrate solution is added to the wells to determine the bound enzyme activity. The color development is stopped and the absorbance is read at 450nm. The intensity of the color is inversely proportional to the concentration of cAMP in the sample. The Y-axis refers to the OD450 obtained by the plate reader and the X-axis refers to the concentration of GLP-1 (7-37) peptide, GLP l (A8G/G22E R36S)-Fn8-NCl and GLP 1 ( A8G/G22E R36S)-Fn8-NCl -54.
Fig. 5 shows the pharmacokinetics profiles of the GLP- 1 containing proteins (GLP- l(A8G/G22E/R36S)-Fn8-COL 18NC 1 ,
GLP-1 (A8G/G22E/R36S)-Fn8-COLl 8NC 1 -20,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COLl 8NC 1 -30 and
GLP- 1 ( A8G/G22E/R36S)-Fn8-COLl 8NC 1 -54) in rats measured by use of the sandwich ELISA method. In this figure, the profiles of these proteins are labeled as NCI , NC20, NC30 and NC54.
Detailed description of the invention
In one aspect of the present invention, there is provided a method to
increase the half life of a therapeutic polypeptide by fusing the therapeutic polypeptide to a scaffold protein via a spacer. The scaffold protein can form a stable homo-trimer in solution. The therapeutic polypeptide is connected to the scaffold protein through a spacer. In some embodiments, the spacer may comprise a flexible, un-structured linker whose length is adjustable (Fig. la). In some embodiments, the spacer may further comprise a proteinous connecting moiety , preferably a proteinous sequence with an elongated shape. The proteinous connecting moiety can be connected to the therapeutic polypeptide and/or the scaffold protein via a flexible, un-structured linker whose length is adjustable (Fig. lb). This novel method provided by the invention, termed as "Trident technology", can efficiently increase the radius of gyration (Rg) of the polypeptide molecule to extend its half life in vivo. Moreover, changing the length of the spacer can adjust the in vivo half life of the fusion protein in a tunable manner.
in preferred embodiments of the present invention, the method of the invention may have several major advantages over the traditional PEGylation method or Fc/HSA fusion method. 1. In the method of the invention, PEGylation on the polypeptide molecule is not essential, therefore the biological activity of the therapeutic polypeptide is fully retained. 2. Because the scaffold protein forms a homo-trimer, the fusion protein of the therapeutic polypeptide with the scaffold protein may greatly increase the apparent size of the fusion protein to slow down renal filtration. Moreover, the trimer formation also renders the fusion protein tri-valency. This may greatly increase the activity of the therapeutic protein. 3. The length of the spacer between the therapeutic polypeptide and the scaffold protein plays an important role in determining the in vivo half life of the fusion protein. The method of the invention provides a platform to fine tune the in vivo half life of a therapeutic polypeptide by varying the length of the spacer within the fusion protein. 4. The scaffold protein is preferably selected from human proteins, usually from human extracellular proteins, therefore, no foreign protein sequences are introduced into the fusion protein. The immunogenicity of the fusion proteins generated using the method is low. 5. In many cases, the
recombinant fusion protein of the therapeutic polypeptide and the scaffold protein can be generated using E.coli expression system, which eliminates the need of the expensive chemical synthesis process for some therapeutic polypeptides or the need of using the eukaryotic expression systems.
5
The scaffold protein
Collagens are a diverse family of proteins that constitute the major structural component of the extracellular matrix 10"12. Collagen is composed of a triple helix, which generally consists of an identical chain (otl ) or an
* o additional chain that differs slightly in its chemical composition (oc2).
Classification according to supramolecular structure assigns collagens to fibril, fibril-associated containing interrupted triple helicies (FACIT), beaded filament, anchoring fibril, network-forming, transmembrane or multiple triple helicies with interruptions (Multiplexin) families13. To date, 43 unique
1 5 a-chains that belong to 28 types of collagens (types I-XXVIII) have been discovered in vertebrates. The alpha chains of collagens consist of at least one triple helical collagenous domain of varying length and two noncollagenous (NC) domains of variable sequence, size, and shape that are positioned at the N and C terminus. The collagenous domains contain the G-X-Y repeats and 0 form the typical triple helix within the collagen molecule while some of the NC domains form homo-trimers to stabilize the collagen triple helix. Studies on classic fibril-forming collagens found that the extreme carboxy-terminal NC (NC I ) domains were essential for trimerization14. The multiplexin family members also utilize NCI domains for trimerization. On the other hand, Fibril associated-collagens (FACIT) have recently been shown to trimerize via their NC2 domains (the second NC domain from the carboxy-terminal end)15 16. The crystal structures of NCI domains from the network-forming collagens IV, VIII and X indicated these NCI domains constituted a stable homo-trimer with the clq-like molecular structure 17~19. About 130 a.a. residues are present in 0 each monomer. In contrast, the NCI domains from the multiplxin family members such as Collagen XV and XVIII formed the much smaller homo-trimer with the length of about 55 residues in each monomer14'20. Both
types of the collagen NC domains form very stable homo-trimers in solution (Tm>60°C) and are suitable as the scaffold protein as described in the invention.
Many other human proteins or domains thereof which can form homo-trimers in solution may also serve as the scaffold proteins in the method of the invention. The Clq family is characterized by a C-terminal conserved globular Cl q domain (pfam ID: PF00386), which can form a stable homo-trimer 21"23. The Cl q-like protein family includes, but not limited to, human C l q A chain, Cl q B chain, Clq C chain, cbln family members, human EMILIN-1 , multimerin, ACRP30/adiponectin, adipolin, resistin and resistin-like molecule (RELM) hormone family members. Tumor necrosis factor (TNF) refers to a cytokine that can induce cell apoptosis and inflammation24'25. TNF family (Pfam ID: PF00229) members include, but not limited, human TNFalpha, TNFbeta, TRAIL, RANK ligand, Fas ligand, CD 30 ligand, CD40 ligand, CD27 ligand, OX40L and CD137. TNF family members form homo-trimers in solution and demonstrated the similar molecular structure as the Clq family members. Therefore, these two family members are also named as Clq/TNF-related proteins (CTRP)22.
The superfamily of proteins containing C-type lectin-like domains (CTLDs, pfam ID: PF00059) is a large group of extracellular proteins with diverse functions including cell-cell adhesion, immune response to pathogens and apoptosis 26. A number of CTLD proteins contain a neck and a C-terminal C-type carbohydrate-recognition domain (CRD) and they form homo-trimer in solution. This type of CTLD includes mannan-binding lectin (MBL), surfactant protein A (SP-A), surfactant protein D (SP-D), collectin liver 1 (CL-L 1 ), collectin placenta 1 (CL-P 1 ), conglutinin, collectin of 43 kDa (CL-43) and collectin of 46 kDa (CL-46), Langerin and Tetranectin 27~30.
In this invention, the CTRP family members, including the Clq-like domains and TNF family members, have been utilized to fuse with the therapeutic polypeptide to extend the in vivo half life of the fusion protein. Alternatively, the CTLD family members can be employed as the scaffold protein to drive the trimerization of the therapeutic polypeptides. Moreover,
the NCI domain within Multiplexin type of human Collagen (such as collagen XV and XVIII) and NC2 domain within FACIT type of collagen (such as collagen IX, XII, XIV, XVI, XIX, XX, XXI, and XXII) may also serve as the scaffold proteins in the method of this invention. The therapeutic polypeptide 5 can be fused to either the N-terminus or the C-terminus of the scaffold protein.
The trimer formation of the fusion protein can efficiently increase the radius of gyration (Rg) of the protein molecule. The fusion protein may demonstrate a much larger apparent size than a compact molecule with the same molecular weight. Therefore the fusion protein will show a much reduced clearing rate i o by renal filtration and will exhibit an extended half life in vivo.
It will be appreciated by a skilled artisan that the term "scaffold protein" as used herein does not necessarily mean an entire wild type protein; a domain or functional variant thereof which can form a stable homo-trimer in solution and can therefore serve the purpose of the invention may also be used in our
1 5 method. In some embodiments of the invention, for example, the C-terminal C lq-like domain of human ACRP30 and the neck and CRD domain of MBL were used as a scaffold protein.
The therapeutic polypeptide
?.o In some embodiments of this invention, the therapeutic polypeptide may be selected from, but not limited to, human glucagon-like peptide- 1 (GLP-1), Calcitonin, human Parathyroid hormone (PTH), G-CSF, GM-CSF, Interferon, VEGF receptors, RANK, TNF receptors, growth hormone, Erythropoietin, single-chain Fv and single domain antibodies. In a preferred embodiment of
25 this invention, we use GLP-1 as one of the examples to illustrate how the method of the invention can significantly improve the pharmacokinetics property of GLP- 1 and its mutants while retaining its biological activity. The natural incretin hormone glucagon-like peptide- 1 (GLP-1) supports glucose homeostasis by enhancing glucose-dependent insulin secretion from ?-cells
30 and suppressing inappropriately elevated postprandial glucagon secretion from a-cells. In addition, GLP-1 has been demonstrated to reduce appetite and food intake and inhibit gastric emptying, which may facilitate weight management
' . Therefore, GLP- 1 remains to be a very promising therapeutic polypeptide for type 2 diabetes and weight loss. However, GLP-1 is a 30 residue polypeptide with a very short half life in vivo, which severely limits its applications. In the present invention, we demonstrated data to show that the half life of GLP-1 can be significantly extended by use of the method of the invention.
One advantage of the method is that it can render tri-valency for the therapeutic polypeptide. It has been well documented that multivalency of protein can greatly enhance its affinity and avidity to binding partner33"35. Antibody IgG is a Y-shaped molecule with bi-valency and utilizes two identical variable domains to interact with its ligand. The fusion protein generated using the method of the invention has tri-valency and therefore might behave better than the traditional human monoclonal antibody IgG in interacting with the ligand. For example, TNF alpha forms a homo-trimer in solution and interact with three TNF receptors simultaneously. To inhibit the TNF alpha function, TNF receptor 2 (TNFR2, p75) have been fused to IgG Fc fragment to constitute Etanercept (Enbrel) to treat severe rheumatoid arthritis. However, one Enbrel molecule can only block two out of three possible binding sites located on TNF alpha homo-trimer. In contrast, our fusion protein of TNFR2 and collagen XVIII NCI domain generated (described below in example 15) can form a homo-trimer and block all three binding sites of TNFalpha while retaining a long half life in vivo.
The scaffold protein utilized in this invention can form homo-trimers by simultaneous self assembly. No inter-chain disulfide bonds are needed to drive the trimerization. Many expression systems such as E. coli, yeast, insect cell and mammalian cell systems can be utilized to express the fusion proteins generated by the invention. In the sharp contrast, therapeutic monoclonal antibodies rely on the mammalian systems for mass productions.
The spacer
In this invention, the therapeutic polypeptide and the scaffold protein are connected by a spacer. In some embodiments, the spacer comprises a flexible
un-structured linker whose length is adjustable.
The term "flexible un-structured linker" refers to an amino acid sequence which is flexible in movement and which does not form any regular stable secondary and tertiary protein structures. The primary sequence of the "flexible un-structured linker" is usually rich in G, S, A, T or P.
If the therapeutic polypeptide is a relatively large protein (such as Interferon, Growth hormone, Erythropoietin, G-CSF, or TNFR2, usually a protein with more than 100 amino acid residues), it may be directly fused to the scaffold protein through a flexible, un-structured linker as the spacer (Fig. l ). In some other cases, the therapeutic polypeptide might be a short peptide (such as GLP- 1 or PTH, usually a peptide not more than 100 residues). To efficiently utilize our method, the spacer between the therapeutic polypeptide and the scaffold protein may contain a proteinous connecting moiety, preferably a proteinous sequence with an elongated shape, such as the human Fibronectin type III domain. The proteinous connecting moiety can be connected to the therapeutic polypeptide and/or the scaffold protein via a flexible, un-structured linker. The proteinous connecting moiety can stabilize and elongate the spacer region within the fusion protein and further increase the radius of gyration (Rg) of the fusion protein. In a particular embodiment of this invention, the proteinous connecting moiety contains a protein domain Fn8. In some embodiments, the proteinous connecting moiety may comprise a whole protein, a truncated version of a protein, a protein domian or domains in tandem, or protein fragments. A skilled artisan will appreciate that the proteinous connecting moiety may comprise some non-proteinous modifications which are not formed by amino acids, such as PEG.
The length of the flexible, unstructured linker may play an important role in determining the radius of gyration (Rg) and the in vivo half life of the fusion protein. The flexible, unstructured linker may contain sequences such as (G4S)n, (G3S)n, (G2S2)n, where n is an integer, or other sequences that are rich in G, S, A, T or P. The length of the flexible linker may vary from 1 to 300 amino acid residues, and particularly within the range of 5 to 100 amino acid residues. It has been reported that the un-structured stretches of
polypeptides may act like PEG molecule and increase the Rg of the protein molecule36. By use of our method, a shorter flexible linker is needed to reach the desired Rg due to the trimer formation compared with the monomer. This may have great advantages for therapeutic proteins by reducing the immunogenecity.
In some embodiments of the invention, the spacer may consist of one flexible, un-structured linker. In some embodiments, the spacer may comprise a first flexible, un-structured linker, a proteinous connecting moiety (preferably a proteinous sequence with an elongated shape), and a second flexible, un-structured linker. It will be appreciated by a skilled artisan that the first flexible, un-structured linker and the second flexible, un-structured linker may be the same or different. In some embodiments of the invention, the proteinous connecting moiety may comprise a whole protein, a single protein domain, or several protein domains in tandem which may be the same or different with each other.
Our data clearly showed that varying the length of the flexible, unstructured linker or linkers can efficiently change the Rg of the molecule and control the in vivo half life of the engineered protein molecule. Therefore, our method can generate a recombinant protein with tunable in vivo half life by varying the flexible, unstructured linker length between the therapeutic polypeptide and the scaffold protein. This is advantageous compared with the traditional therapeutic IgG with fixed in vivo half life. In addition, our method may offer the fusion protein tri-valency for the ligand, in contrast, IgG only has bi-valency.
Fibronectin(Fn) is a high-molecular weight (~440kDa) glycoprotein of the extracellular matrix that binds to a number of proteins including integrins, collagen, fibrin and heparan sulfate proteoglycans (e.g. syndecans) Fibronectin exists as a protein dimer, consisting of two nearly identical polypeptide chains linked by a pair of C-terminal disulfide bonds. Each fibronectin monomer has a molecular weight of 230-250 kDa and contains three types domains: type I, II, and III. Type I and type II are stabilized by intra-chain disulfide bonds, while fibronectin type III domains do not contain
12 001723
any disulfide bonds The Fibronectin type III domain is an evolutionary conserved protein domain that is widely found in animal proteins. The human fibronectin protein in which this domain was first identified contains 16 copies of this domain (Fnl to Fnl 6). The fibronectin type III domain family (pfam ID: PF00041 ) member contains about 95 amino acids long and possesses a beta sandwich structure. Fibronection type III domain forms a very stable domain structure with the melting temperature of -70 °C as measured by DSC 39,4°. Fibronectin type III domains are found in a wide variety of extracellular proteins. In human genome, fibronection type III domain exists in many proteins including Tenascin, Usherin, Titin, tripartite motif (TRIM) family members, tissue factor, TIE1 , TIE2, SPEG, SORL1 , SDK1 , ROBOl , ROB02, SD 2, Receptor-type tyrosine-protein phosphatase, prolactin receptor, L I CAM, NCAM1 , NCAM2, myomesin 1 , myomesin 2, Myosin-binding protein C, LIFR, Leptin receptor, Integrin, Insulin receptor, Contactin, Collagen, Cytokine receptor-like factor, Inteferon receptor, Growth hormone receptor, fibronectin, leucine rich transmembrane protein (FLRT) members, IL, ephrin type-A receptor, ephrin type-B receptor, IL-6R, gpl30, IL1 1RA, IL 12RB, IL20RB, IL23R, IL27RA and IL31RA etc. Therefore, using Fibronectin type III domain as part of the spacer in our method may have low immunogenicity. The Fibronectin type III domains can also be used in tandem fashion in the spacer. In addition, Fibronectin type III domain can be expressed in recombinant form using a number of expression systems including E. coli, using Fibronectin type III domain as part of the spacer in the method of the invention may greatly increase the expression yield of the fusion protein.
Summary for Trident technology
Improving the pharmacokinetic property of a therapeutic polypeptide may have major impacts on its application. In one aspect, the present invention provides a novel technique termed as "Trident technology" which allows the therapeutic polypeptide to fuse with a scaffold protein which forms homo-trimer through a spacer with variable length. The trimer formation may
greatly increase the Rg of the fusion molecule and improve the in vivo half life of the fusion protein. The scaffold proteins can be fused to the N-terminus or C-terminus of the therapeutic polypeptide. The length of the spacer between the therapeutic polypeptide and the scaffold protein can be modified to fine tune the pharmacokinetics feature of the fusion protein. Moreover, the method of the invention can provide the therapeutic polypeptide with tri-valency, which may greatly increase the affinity and avidity of the fusion protein toward the ligand.
To further extend the in vivo half life of the fusion protein generated by the method of the invention, the fusion protein can be further modified by PEGylation. The PEG moiety may have a molecular weight of between 2 and 100 kDa. For specific PEGylation, the Cys residue may need to be generated in the fusion protein using site-directed mutagenesis.
The terms "protein", "polypeptide" and "peptide" as used here are interchangeable, unless instructed to the contrary.
The term "functional variant" of a protein refers to a modified version of the native protein which comprises substitutions, deletions and/or additions of one or several amino acids, e.g., less than 15 amino acids, or preferably less than 10 or 5 amino acids, and which substantially retains the biological activity of the native protein. Typically, conservative substitutions of amino acids are preferred which are well known to a skilled artisan. Deletions are preferably deletions of amino acids from regions not involved in the biological function of the protein. For example, GLP-1 (A8G/G22E) is a functional variant of wild type GLP- 1 , which contains two substitutions of amino acids and which substantially retains its biological activity such as increasing cAMP level.
Methods of Preparing fusion proteins generated by the Present Invention_
The fusion proteins of the present invention can be produced through the application of recombinant DNA technology. Recombinant polynucleotide constructs encoding a fusion polypeptide of the present invention typically include an expression control sequence operably-linked to the coding
sequences of the fusion polypeptide, including naturally-associated or heterologous promoter regions. As such, another aspect of the invention includes vectors containing one or more nucleic acid sequences encoding a fusion polypeptide of the present invention. For recombinant expression of one 5 or more polypeptides of the invention, the nucleic acid containing all or a portion of the nucleotide sequence encoding the fusion polypeptide is inserted into an appropriate cloning vector, or an expression vector (i.e., a vector that contains the necessary elements for the transcription and translation of the inserted polypeptide coding sequence) by recombinant DNA techniques well s o known in the art and as detailed below. Methods for producing diverse populations of vectors have been described by Lerner et al., U.S. Pat. No. 6,291 , 160; 6,680,192.
In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids. In some embodiments of the present invention,
1 5 "plasmid" and "vector" can be used interchangeably as plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors that are not technically plasmids, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions. Preferably, the 0 expression control sequences are eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences encoding the fusion polypeptide. These expression vectors are typically 5 replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers, e.g. , ampicillin-resistance or kanamycin-resistance, to permit detection of those cells transformed with the desired DNA sequences. Vectors can also encode a signal peptide, e.g., pectate lyase, useful to direct the
30 secretion of extracellular antibody fragments. See U.S. Pat. No. 5,576, 195.
The recombinant expression vectors of the invention may comprise a nucleic acid encoding a fusion polypeptide in a form suitable for expression of
12 001723
the nucleic acid in a host cell, which means that the recombinant expression vectors may include one or more regulatory sequences selected on the basis of the host cells to be used for expression that are operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, 5 "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g. , in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other
1 0 expression control elements (e.g. , polyadenylation signals). Such regulatory sequences are described, e.g. , in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. ( 1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and
! 5 those that direct expression of the nucleotide sequence only in certain host cells (e.g. , tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, etc.
?.o Another aspect of the invention pertains to the fusion polypeptide-expressing host cells, which contain a nucleic acid encoding one or more fusion polypeptides. The recombinant expression vectors of the invention can be designed for expression of a fusion polypeptide in prokaryotic or eukaryotic cells. For example, a fusion polypeptide can be
25 expressed in bacterial cells such as Escherichia coli, insect cells, fungal cells, e.g. , yeast, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 1 85, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and
30 translated in vitro, e.g. using T7 promoter regulatory sequences and T7 polymerase.
Expression of polypeptides in prokaryotes is most often carried out in E.
23
coli with vectors containing constitutive or inducible promoters directing the expression of the recombinant polypeptides. The vectors may add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such vectors with extra amino acid residues 5 typically serve three purposes: (i) to increase expression of recombinant polypeptide, (ii) to direct the recombinant protein to periplasmic space; and (iii) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Typical expression vectors serving this purpose include pGEX (GE Healthcare), pMAL (New England Biolabs), pET20b(Novagen),
! o pET43b (Novagen), pET32b(Novagen) and pRIT5 (GE Healthcare).
Examples of suitable inducible E. coli expression vectors include pTrc vectors (Invitrogen), pQE (Qiagen) and pET vectors (Novagen). One strategy to maximize recombinant polypeptide expression is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the
1 5 individual codons for each amino acid are those preferentially utilized in the expression host, e.g., E. coli 41. Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the fusion polypeptide expression vector is a yeast expression vector. Examples of vectors for expression in yeast 0 Saccharomvces cerivisae include pYES2 (Invitrogen), pMFa42 and pJRY8843.
The fusion protein may also be expressed in Pichia system using the vectors pPICZ pGAPZ and pPIC9(InVitrogen). Alternatively, a fusion polypeptide can be expressed in insect cells using baculovirus expression vectors or using the stable insect cell lines. Baculovirus systems available for expression of 5 polypeptides in cultured insect cells {e.g. , SF9 cells) include the BaculoGold system (BD Biosciences), BaculoDirect system (Invitrogen) and BacVector system (Novagen). The stable insect expression systems include, but not limited to, DES system (Invitrogen) and InsectDirect (Novagen).
In another embodiment, a nucleic acid encoding a fusion polypeptide of 0 the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include, e.g., but are not limited to, pcDNA3. 1 (Invitrogen), pSecTag (invitrogen), and pTriEx series
vectors (Novagen). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells useful for expression of the fusion polypeptide of the present invention, please see, e.g., Chapters 16 and 17 of Sambrook, et al , MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
In the eukaryotic expression systems, the recombinant fusion protein can be expressed in the cytoplasm. Or alternatively, the fusion protein can be secreted into the medium by adding an N-terminal secretion signal.
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention is to be introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, a fusion polypeptide can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells. Mammalian cells are a preferred host for expressing nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes To Clones, (VCH Publishers, NY, 1987). A number of suitable host cell lines capable of secreting intact heterologous proteins have been developed in the art, and include Chinese hamster ovary (CHO) cell lines, 293 cells, various COS cell lines, HeLa cells, L cells and myeloma cell lines. Preferably, the cells are nonhuman. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites,
and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papillomavirus, and the like. Other suitable host cells are known to those skilled in the art.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate a foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding the fusion polypeptide or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. , cells that have incorporated the selectable marker gene will survive, while the other cells die).
Once expressed, the fusion polypeptides are purified from culture media and/or host cells. Purification of recombinant polypeptides is well known in the art and includes ammonium sulfate precipitation, affinity chromatography purification technique, column chromatography, ion exchange purification technique, gel filtration and the like (see generally Scopes, Protein Purification (Springer- Verlag, N.Y., 1982).
Formulation of Pharmaceutical Compositions
The present invention envisions treating a disease, for example, type II diabetes, in a mammal by the administration of the fusion protein compositions of the present invention. Administration of the fusion protein in accordance with the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners. The administration of the vaccines of the invention may be essentially continuous over a preselected period of time
or may be in a series of spaced doses. Both local and systemic administration is contemplated.
The pharmaceutical composition of the present invention may be delivered via various routes and to various sites in a mammal body to achieve a particular effect. One skilled in the art will recognize that although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, peritoneal, subcutaneous, intradermal, as well as topical administration.
The amount of the administered fusion protein of the present invention will vary depending on various factors including, but not limited to, the particular disease, the weight, the physical condition, and the age of the mammal, and whether prevention or treatment is to be achieved. Such factors can be readily determined by the clinician employing animal models or other test systems which are well known to the art. Generally, the amount of the fusion protein of the present invention to be administered to a mammal subject may vary in the range of l ng/kg to l OOmg/kg of the subject body weight. In an embodiment of the invention, the amount of administration was from 0.5mg/kg to l .Omg/kg.
When the fusion proteins of the invention are prepared for administration, they are preferably combined with a pharmaceutically acceptable carrier to form a pharmaceutical formulation, or unit dosage form. Commonly used pharmaceutically acceptable carriers are well known to a skilled artisan in the field of pharmacy. The total active ingredients in such formulations include from 0. 1 to 99.9% by weight of the formulation. The active ingredient for administration may be present as a powder or as granules; as a solution, a suspension or an emulsion.
Thus, the therapeutic agent may be formulated for parenteral administration (e.g. , by injection, for example, bolus injection or continuous
infusion) and may be presented in unit dosage form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative. The active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for re-constitution with a suitable vehicle, e.g. , sterile, pyrogen-free water, before use.
In general, water, suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain the active ingredient, suitable stabilizing agents and, if necessary, buffer substances. Antioxidizing agents such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium ethylenediaminetetraacetic acid (EDTA). In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl -paraben and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field
Additionally, standard pharmaceutical methods can be employed to control the duration of action. These are well known in the art and include control release preparations and can include appropriate macromolecules, for example polymers, polyesters, polyamino acids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate. The concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release. Additionally, the agent can be incorporated into particles of polymeric materials such as polyesters, polyamino acids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.
The terms "pharmaceutically-acceptable," "physiologically-tolerable," and grammatical variations thereof, as they refer to compositions, carriers, and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a subject without the production of undesirable physiological effects to a degree that would prohibit administration of the composition.
Preferred examples of such carriers include, but are not limited to, water, saline, Ringer's solutions, and dextrose solution. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the fusion polypeptides, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. The fusion polypeptides compositions of the present invention can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intradermal, transdermal, rectal, intracranial, intraperitoneal, intranasal; intramuscular route or as inhalants. The fusion polypeptides can optionally be administered in combination with other agents that are at least partly effective in treating various diseases including various actin- or microfilament-related diseases.
Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be
enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, e.g. , by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, e.g. , parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic compounds, e.g. , sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, e.g. , aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the fusion polypeptides in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the binding agent into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yield a powder of the
active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The agents of this invention can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient.
Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the binding agent can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding compounds, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin, an excipient such as starch or lactose, a disintegrating compound such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening compound such as sucrose or saccharin; or a flavoring compound such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the fusion polypeptides are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, e.g. , for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the fusion polypeptides are
formulated into ointments, salves, gels, or creams as generally known in the art.
The fusion polypeptides can also be prepared as pharmaceutical compositions in the form of suppositories (e.g., with conventional suppository 5 bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
Examples
The present invention is further illustrated by the following examples, l o which should not be construed as limiting in any way.
Example 1. Construction of an expression vector of GLP-1 fused with human Fibronectin type III domain 7 (Fn7) and human collagen XVIII NC I domain (COL 1 8NC 1 )
In this example, GLP- 1 polypeptide was fused to the N-terminus of i s the human collagen XVIII NC I domain (COL1 8NC 1 ) which forms a stable homo-trimer. To further extend the Rg of the molecule, the human Fibronectin type III domain 7 (Fn7) was connected to the GLP-1 polypeptide and COL1 8NC 1 through two flexible, unstructured linkers 1 and 2 (linker 1 : GGGSGGGG, linker 2: GGGSGG). The pET29b vector
?.o (Novagen) was used to construct a recombinant plasmid containing the GLP- 1 -Fn7-C0L 1 8NC1 fusion gene. First, human COL 1 8NC 1 was cloned into pET29b by BamHl and Xho\ to result in the pET29b-COL 1 8NC l vector. PCR reaction was carried out using human collagen XVIII cDNA as the template by using the following primers:
25 Col 1 8NC 1 -forward:
CGGGATCCGGTGGCGGCGCCTCCTCAGGGGTGAGG
Col 1 8NC 1 -reverse:
CCGCTCGAGTTACCCTCGTGGGAGTGGTGTCCGGGCCTCC
The PCR product was digested by restrictive enzyme B mHl and Xhol 30 (Fermentas) and ligated into the pET29b vector by use of T4 ligase (Fermentas). The sequence of resulted pET29b-COL18NCl vector was confirmed by DNA sequencing.
PCR reaction was carried out using human Fibronectin cDNA as the template by using the following primers:
Glpl -Fn7-Forward:
GGAATTCCATATGCATGCCGAAGGGACTTTTACCAGTGATGTAAGTTCTTAT
5 TTGGAAGGTCAAGCTGCAAAAGAATTCATTGCTTGGCTGGTGAAAGGCCGTG GTGGTGGCGGCTCTGGTGGCGGTGGCACACCATTGTCTCCACCAACAAACTT GCATCTG
Glp1 -Fn7-Reverse:
C G G GAT C C AC C AC C AG C T G G GAT GAT GG T AT C AG AG AT AG G G AC AC T T T C C
! 0 The PCR product was digested by restrictive enzyme Ndel and BamWl
(Feimentas) and Iigated into the digested pET29b-COL1 8NCl vector. The optimized DNA sequence of human GLP-1 (7-37) was included in the primer named as Glpl -Fn7-Forward. The cloned GLP- 1 -Fn7-C0L18NC 1 fusion gene was confirmed by DNA sequencing. The protein sequence of : 5 GLP- 1 -Fn7-C0L1 8NC 1 was listed as SEQ ID NO: 1 .
SEQ ID NO: 1 , GLP- 1 -Fn7-C0L18NC 1 protein sequence. Fn7 is connected to GLP-1 and COL18NC1 by use of two flexible unstructured linkers 1 and 2. The flexible, unstructured linker 1 between GLP- 1 and Fn7 (GGGSGGGG) is underlined. The flexible, unstructured linker 2 (GGGSGG) between Fn7 and COL18NC1 is also underlined. GLP-1 sequence is in italic.
/lAEGTFTSDVSSYLEGOAAKEFlA WLVKGRGGGGSGGGG
TPI .SPPTNLHL EANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTV D D ESVP1SDTI1PAGGGSGGGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFR VQLEARTPLPRG
Example 2. Cloning of GLP- 1 fused with Fibronectin type III domain 8 (Fn8) and human collagen XVIII NC I domain (COL 1 8NC1 )
Other human Fibronectin type III domains may also act as part of the spacer between the therapeutic polypeptide and the scaffold protein in our method. In this example, we showed that Fibronectin type III domain 8 (Fn8) can be utilized as part of the spacer between GLP- 1 and collagen XVIII NC I domain. The gene encoding human Fibronectin type III domain 8 (Fn8) was amplified by PCR using the following primers and
human Fibronectin cDNA as the template:
Fn8-Forward:
GGAATTCCATATGCATGCCGAAGGGACTTTTACCAGTGATGTAAGTTCTTAT TTGGAAGGTCAAGCTGCAAAAGAATTCATTGCTTGGCTGGTGAAAGGCCGTG GTGGTGGCGGCTCTGGTGGCGGTGGCTCTGCTGTTCCTCCTCCCACTGACCT GCGATTC
Fn8-Reverse:
CGGGATCCACCACCACCTGTTTTCTGTCTTCCTCTAAGAGGTGTGC
The PCR product was digested by Ndel and BamHl. The digested insert was ligated into the digested vector pET29b-COL1 8NC l (generated in example 1 ). The resulted vector was named as pET29b-GLP- l -Fn8-COL 1 8NC l . The protein sequence of the fusion protein GLP- l -Fn8-COLl 8NC 1 was listed as SEQ ID NO: 2.
SEQ ID NO: 2, GLP-1 -Fn8-C0L18NC1 protein sequence, GLP-1 sequence is in italic. Fn8 is connected to GLP- 1 and COL 18NC 1 by use of two flexible unstructured linkers 1 and 2. The flexible, unstructured linker 1 between GLP- 1 and Fn8 (GGGSGGGGS) is underlined. The flexible, unstructured linker 2 (GGGSGG) between Fn8 and COL18NC1 is also underlined.
IL EGTFTSDVSSYLEGQAiKEFIAHlVKGRGQGGSOG^^
NEEDV.AELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTG
GGGSGGGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
Example 3. Expression and Purification of fusion protein GLP- 1 -Fn8-C0L1 8NC 1
The constructed expression vector pET29b-Glpl -Fn8-COL1 8NC l , after sequencing confirmation, was used to transform Escherichia coli BL2 1 (DE3) for protein expression (for detailed protocols of the transformation, see Molecular Coining: A Laboratory Manual). A single colony was selected from the culture dish, and placed into a 10 ml LB liquid medium with kanamycin (final concentration, 50 μg/ml), then shaken at 37 °C at 220 rpm overnight. 1 L LB culture was inoculated and allowed to grown until OD6oo reached 0.4- 1.0. Isopropyl thiogalactoside
(1PTG) was added to a final concentration of 0.2mM. After a successive culture at 30 °C for overnight, cells were collected by centrifugation. The cells were diluted 1 : 20 with 20mM Tris, NaCl 50mM, 2mM EDTA, pH 8.0, and, after a thorough mix, disrupted by sonication. Insoluble 5 precipitates were removed by centrifugation at 13 ,000 RCF for 30 min.
The proteins of interest were present in the supernatant, with the expressed product comprising 20% of soluble proteins. 50ml of the supernatant was loaded on a HiTrap Q column (5ml) (GE healthcare). The fusion protein of GLP1 -Fn8-C0L 1 8NC 1 was eluted with about 0.3 M NaCl in the buffer. ! 0 The eluted protein was further purified by gel filtration column S-200 (GE Healthcare), and the buffer was replaced with PBS (pH 7.5). The final product was confirmed by SDS-PAGE electrophoresis.
Example 4: GLP- 1 mutants fused with Fn8-C0L1 8NC 1
1 5 The mutations of A8G/G22E, A8V/G22E, A8S/G22E and
A8G/G22E/R36S within the Glp- 1 sequence may increase its resistance to protease digestion, reduce immunogenicity and boost its biological activity '44. In this example, we constructed a vector to fuse GLP- 1 (A8G/G22E) with Fibronectin type III domain 8 and collagen XVIII NC I domain. The 0 PCR reaction was carried out using vector pET29b-GLP 1 -Fn8-COL 1 8NC 1 prepared in example 2 as the template with the following primers:
Glp- 1 (A8G/G22E)-Fn8-forward:
GGAATT CCATATGCATGGCGAAGGGACTTTTACCAGTGATGTAAGTTCTTAT
T T GG AAG AG C AAG C T G C AAAAG AAT T CAT T G C
25 Col l 8NC 1 -reverse:
CCGCT CGAGT TACCCTCGTGGGAGTGGTGTCCGGGCCT CC
The PCR product was digested by Nde\ and Xhol (Fermentas). The digested insert was ligated into the digested vector of pET29b. The resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NC l .ί θ The expression and purification protocol of the fusion protein of
GLP- 1 (A8G/G22E)-Fn8-C0L 1 5NC 1 was the same as described in example 3. Other mutations, such as A8V/G22E, A8S/G22E and
A8G/G22E/R36S, within the GLP- 1 can be generated using the Quikchange II site-directed mutagenesis kit (Agilent) using the GLP- 1 (A8G/G22E)-Fn8-C0L 1 5NC 1 gene as the template. The protein sequences of these GLP l mutants fused with Fn8-C0L 1 8NC 1 were listed as SEQ ID NO. 3-6. The expression and purification protocol of these fusion proteins can be carried out using similar protocols described in example 3.
SEQ ID NO: 3, GLP- 1 (A8G/G22E)-Fn8-C0L18NC 1 protein sequence, the GLP-1 mutation sites
(A8G/G22E) are underlined.
HGEGTFTSDVSSYLEEQAAKEFIAWLV G GGGGSGGGGSAVPPPTDLRFTNIGPDT RVTWAPPPSIDLTNFLVRYSPVK NKEDVAELSISPSDNAVVLT LLPGTEYVVSVSSVYEQHESTPLRGRQKTG
GGGSGGGASSGVRLWATRQAMLGQVHEVPEGWUFVAEQEELYVRVQNGFRKVQLEARTPLPRG
SEQ ID NO: 4, GLP- 1 (A8V/G22E)-Fn8-C0L18NC1 protein sequence, the GLP-1 mutation sites
(A8V/G22E) are underlined.
HVEGTFTSDVSSYLEEQAAKEFIAWLV GRGGGGSGGGGSAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK NEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG
GGGSGGGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFR VQLEARTPLPRG
SEQ ID NO: 5, GLP-1 (A8S/G22E)-Fn8-C0L18NC1 protein sequence, the GLP-1 mutation sites
(A S/G22E) are underlined.
H EGTFTSDVSSYLEEQAAKEFIAWLVKGRGGGGSGGGGSAVPPPTDLRFT IGPDTMRVTWAPPPSIDLTNFLVRYSPVK NEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG
GGGSGGGASSGVRLWATRQA LGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
SEQ ID NO: 6, GLP-l (A8G/G22E/R36S)-Fn8-C0L18NCl protein sequence, the GLP-1 mutation sites
(A8G/G22E R3GS) are underlined.
ilGEGTFTSDVSSYLEEQAAKEFIAWLVKGSGGGGSGGGGSAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPV NEEDVAELS1SPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTG
GGGSGGGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
Example 5 : Cloning and expression of GLP- 1 (A8G/G22E) fused with Tenascin C fibronectin type III domain 3 (TNCfn3) and human collagen XVI11 NC I (COL 1 8NC1 )
In this example, we demonstrated that the fibronectin type III domain that can be used as part of the spacer for our method is not limited within human fibronectin. Other suitable fibronectin type III domain may alternatively be utilized in the spacer in the method of the invention. Here we showed that a fibronectin type III domain from human Tenascin C can be utilized as part of the spacer between the therapeutic polypeptide and the scaffold protein as well.
In this example, the human Tenascin C fibronectin type III domain 3 (TNCfn3) was connected to the GLP- 1 polypeptide and COL1 8NC 1 through two flexible, unstructured linkers 1 and 2 (linker 1 : GGGSGGGGS, linker 2: GGGSGG). The gene encoding TNCfn3 was amplified by PCR using human Tenascin C cDNA as template using the following primers : TNCfn3-Forward.
GGAATTCCATATGCATGGCGAAGGGACTTTTACCAGTGATGTAAGTTCTTAT TTGGAAGAGCAAGCTGCAAAAGAATTCATTGCTTGGCTGGTGAAAGGCCGTG GTGGTGGCGGCTCTGGTGGCGGTGGCTCTCGCTTGGATGCCCCCAGCCAGAT CGAGG
TNCfn3 -Reverse:
CGGGATCCACCACCGCCTGTTGTGAAGGTCTCTTTGGCTG
The PCR product was digested by Ndel and BamUl (Fermentas). The digested insert was ligated into the digested vector pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NC l as prepared in example 4. The resulted vector was named as pET29b-GLP l (A8G/G22E)-TNCfn3-COL 1 8NC l . The expression and purification protocol of the fusion protein GLP l (A8G/G22E)-TNCfn3-COL 18NC l (SEQ ID NO:7) was the same as described in example 3.
SEQ ID NO: 7, GLP-l -TNCfn3-COL18NCl protein sequence, the TNCfn3 sequence is in italic. TNCfn3 is connected to GLP-1 and COL18NC1 by use of two flexible unstructured linkers 1 and 2. The flexible, ! unstructured linker 1 between GLP-1 and TNCfn3 (GGGSGGGGS) is underlined. The flexible, unstructured linker 2 (GGGSGG) between TNCfn3 and COL18NC 1 is also underlined.
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGGGGSGGGGS
RLDA PSQ1E VKD VTD TEA LITWFKPLA EIDGIEL TYGIKD VPGDR TTIDL TEDENQ YSIGNLKPD TE YE VSLI SRR GDMSSNPA KETFTTG
GGGSGGGASSGVRLWATROAMLGQVHEVPEGWLIFVAEOEELYVRVONGFRKVOLEARTPLPRG
Example 6 : Cloning and expression of GLP-1 (A8G/G22E) fused with Fn8 and human collagen XV NC I (COL 15NC1 )
In this example, we presented data to show that the NCI domain from collagen XV can alternatively be utilized as the scaffold protein in our method. It has been reported that human collagen XV NC I domain, like the human collagen XVIII NC I domain, forms a stable homo-trimer14'20. To generate the expression vector encoding the fusion protein of GLP 1 (A8G/G22E)-Fn8-C0L 15NC 1 , PCR reaction was carried out using human collagen XV cDNA as the template by using the following primers: Col 1 5NC 1 -forward:
CGGGAT CCGGTGGCAACCTGGTCACAGCATTCAGCAACATGG
Col 1 5NC 1 -reverse:
CCGCTCGAGTTAGGCAGGAATGGGGATCAGTTCT CCCAG
The PCR product was digested by restrictive enzyme BamWl and Xhol
(Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NCl vector as prepared in example 4 by use of T4 ligase (Fermentas). The resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-COL1 5NC l and the sequence of the vector was confirmed by DNA sequencing. The protein sequence of GLP 1 (A8G/G22E)-Fn8-C0L1 5NC 1 was listed as SEQ ID NO: 8. The expression and purification protocol of the fusion protein GLP 1 (A8G/G22E)-Fn8-C0L1 5NC 1 (SEQ ID NO: 8) was the same as described in example 3.
SEQ ID NO: 8, GLP- 1 (A8G/G22E)-Fn8-C0L15NC 1 protein sequence, the sequence of COL15NC1 is underlined. The flexible unstructured linker 1 (GGGSGGGGS) between GLP- 1 and Fn8 is in italic. The flexible unstructured linker 2 (GGGSGG) between Fn8 and COL15NC1 is also in italic.
HGEGTFTSDVSSYLEEQAAI EFIAWLVKGRGGGG5GGGG5AVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK NEEDVAELSISPSDNAVVLT LLPGTEYVVSVSSVYEQHESTPLRGRQ TG
(;GG,V (7NLVTAFSNMDD LOKAHLVIEGTFIYLRDSTEFFIRVRDGWK LOLGELIPIPA
Example 7: Cloning and expression of GLP- 1 (A8G/G22E) fused with Fn8 and human collagen XIX NC2 domain (COL19NC2)
In this example, we demonstrated that the NC2 domain from collagen
XIX can be utilized as the scaffold protein in our method. It has been shown that human collagen XIX NC2 domain (COL 19NC2) forms a highly stable homo-trimer16. To generate the expression vector encoding the fusion protein of GLP l (A8G/G22E)-Fn8-COL19NC2, PCR reaction was carried out using human collagen XIX cDNA as the template by using the following primers:
Col l 9NC2-forward:
CGGGATCCGGTGGCGGCATT CCGGCTGATGCAGTTTC
Col l 9NC2-reverse:
CCGCTCGAGTTAAGGTCTCCCATAAGCTTGGGCAGCCAAC
The PCR product was digested by restrictive enzyme BamUl and Xho\ (Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NC l vector as prepared in example 4 by use of T4 ligase (Fermentas). The resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-COL19NC2 and the sequence of the vector was confirmed by DNA sequencing. The protein sequence of GLP l (A8G/G22E)-Fn8-COL 19NC2 was listed as SEQ ID NO:9. The expression and purification protocol of the fusion protein GLP l (A8G/G22E)-Fn8-COL 19NC2 (SEQ ID NO:9) was similar as that was described in example 3.
SEQ ID NO: 9, GLP-l (A8G/G22E)-Fn8-COL19NC2 protein sequence, the sequence of COL19NC2 is underlined. The flexible unstructured linker 1 (GGGSGGGGS) between GLP- 1 and Fn8 is in Italic. The flexible unstructured linker 2 (GGGSGG) between Fn8 and COL19NC2 is also in italic.
HGEGTFTSDVSSYLEEQAA EFIAWLVKGRGGGGSGGGG5AVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK NF.F.DVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG
GGGSGGGIPADAVSFEEIKKYINQEVLRIFEER AVFLSQLKLPAA LAAQAYGRP
Example 8: Cloning and expression of GLP- 1 (A8G/G22E) fused with Fn8 and human ACRP30 C-terminal Cl q-like domain
ACRP30 (also referred to as Adiponectin, GBP-28, apMl and AdipoQ) is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism45. ACRP30 contains a C-terminal globular domain that forms a homo-trimer with typical Clq-like structure 46. In this example, we demonstrated that the Cl q-like domain, such as the ACRP30 C l q-like domain, can be utilized as the scaffold protein in our method. To generate the expression vector encoding the fusion protein of GLP 1 (A8G/G22E)-Fn8-ACRP30, PCR reaction was carried out using human ACRP30 cDNA as the template by using the following primers: ACRP30-forward:
CGGGATCCGGTGGCGTA ACCGCTCAGCATTCAGTGTGG ACRP30-reverse:
C C G C T C G AGT TAT C AGT T GGT G T CAT GG T AGAGAAG
The PCR product was digested by restrictive enzyme BamHl and Xhol (Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL 1 8NCl vector as prepared in example 4 by use of T4 ligase (Fermentas). The resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-ACRP30 and the sequence of the vector was confirmed by DNA sequencing. The protein sequence of GLP 1 (A8G/G22E)-Fn8-ACRP30 was listed as SEQ ID NO: 10. The expression and purification protocol of the fusion protein GLP 1 (A8G/G22E)-Fn8-ACRP30 (SEQ ID NO: 10) is similar as described
in example 3.
SEQ ID NO: 10, GLP- 1(A8G/G22E)-Fn8-ACRP30 protein sequence, the sequence of ACRP30 Cl q-like domain is underlined. The flexible unstructured linker 1 (GGGSGGGGS) between GLP-1 and Fn8 is in italic. The flexible unstructured linker 2 (GGGSGG) between Fn8 and ACRP30 is also in italic.
HGEGTFTSDVSSYLEEQAA EFIAWLVKGRGGGG5GGGGSAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVK
NEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPL G QKTG
GGG5GGVYRSAFSVGLETRVTVPNVPIRFTKIFYNQQNHYDGSTG FYCNIPGLYYF5YHITVYMKDVKV
SLFK D AVLFTYDQY EKNVDQASGSVLLHLEVGDQVWLQVYGDGDHNGlYADNVNDSTFTGFLLY
HDTN
Example 9. Cloning and expression of GLP- 1 (A8G/G22E) fused with Fn8 and human mannose-binding lectin ( BL) neck and CRD domain.
Human mannose-binding lectin (MBL) is a calcium-dependent lectin that plays important roles in innate immune defense47'48. MBL belongs to the C-type lectin-like domain (CTLD) family and the long helix neck region and the C-terminal carbohydrate recognition domain (CRD) of MBL form a homo-trimer29. In this example, we demonstrated that the human MBL neck and CRD domain can be utilized as the scaffold protein in our method. To generate the expression vector encoding the fusion protein of GLP 1 (A8G/G22E)-Fn8-MBL, PCR reaction was carried out using human MBL cDNA as the template by using the following primers:
MBL-forward:
CGGGATCCGGTGGCGGT GATAGTAGCCTGGCTGCC MBL-reverse:
C C G C T C GAGT C AGAT AGG GAAC T C AC AG AC GG C C AG
The PCR product was digested by restrictive enzyme BamHl and Xhol (Fermentas) and ligated into the digested pET29b-GLP l (A8G/G22E)-Fn8-COL1 8NC l vector as prepared in example 4 by use of T4 ligase (Fermentas). The resulted vector was named as pET29b-GLP l (A8G/G22E)-Fn8-MBL and the sequence of the vector was
confirmed by DNA sequencing. The protein sequence of GLP 1 (A8G/G22E)-Fn8-MBL was listed as SEQ ID NO: 1 1. The expression and purification protocol of the fusion protein GLP 1 (A8G/G22E)-Fn8-MBL (SEQ ID NO: 1 1 ) was similar as described in example 3.
SEQ ID NO: 1 1 , GLP-1(A8G/G22E)-Fn8-MBL protein sequence, the sequence of the neck and CRD domain of MBL is underlined. The flexible unstructured linker 1 (GGGSGGGGS) between GLP-1 and Fn8 is in italic. The flexible unstructured linker 2 between Fn8 and MBL is italicized.
HG1.GTFTSDVSSYI.EEQAAKEFIAWLVKGRGGGG5GGGG5AVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPV Nl- I- DVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG
GGG5GG
G SSLAASER ALOTEMARIKKWLTFSLGKOVGNKFFL
I NGEIMTFEKVKALCVKFQASVATPRNAAENGAIQNLIKEEAFLGITDEKTEGOFVDLTGNRLTYT WNE GEPNNAGSDEDCVLLLKNGOWNDVPCSTSHLAVCEFPI
Example 10. Between the therapeutic polypeptides and the scaffold proteins, various spacer lengths can be used to generate the fusion proteins with the desired radius of gyration (Rg)
In this example, we presented data to demonstrate that the flexible unstructured linkers with various lengths can be utilized in our method to adjust the Rg of the fusion protein. It is well established that a protein with a larger Rg may exhibit a longer half life in vivo. Therefore, the method of the invention may adjust the in vivo half life of the therapeutic polypeptide in a tunable fashion.
In the fusion protein of GLP-1 (A8G/G22E)-Fn8-C0L18NC 1 described in example 4, the flexible unstructured linker 2 between Fn8 and COLl 8NC 1 contains six residues (GGGSGG). To generate the flexible linkers with different lengths, we have synthesized the genes
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -20,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
GLP- l (A8G/G22E/R36S)-Fn8-COL18NCl -60. In these genes, the length of the flexible linker 2 between Fn8 and COL18NC1 contained 20, 30, 54 and 60 residues, respectively. The protein sequences of
GLP- 1 (A8G/G22E/R36S)-Fn8-COLl 8NC1-20,
5 GLP-1 ( A8G/G22E/R36S)-Fn8-COL 1 8NC 1 -30,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
GLP-l (A8G/G22E/R36S)-Fn8-COL 18NCl -60 are listed as SEQ ID NO:
12-14 and 21 . The synthetic genes of
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -20,
! o GLP- 1 (A8G/G22E/R36S)-Fn8-COL 1 8NC1 -30,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -60 were grafted to the pET29b by Ndel and Xho\ for protein expressions. The expression and purification of these fusion proteins were carried out using similar protocols described in
1 5 example 3. Fig. 2 showed the purified proteins of
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC1 ,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC1 -20,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC1 -30,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -54 and
0 GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -60 using SDS-PAGE analysis. To estimate the Rg of the fusion proteins, the purified proteins were loaded on an analytical gel filtration column Superdex200 (GE Healthcare). Fig. 3 showed the chromatography profiles for these fusion proteins.
The gel filtration data clearly showed that varying the length of the 5 flexible, unstructured linker between Fn8 and COL1 8NC1 can significantly change the apparent molecular size of the fusion proteins in solution (Fig. 3). GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -60 trimer exhibited an apparent molecular weight of ~170Kd but its genuine molecular weight is ~80Kd. GLP- 1 (A8G/G22E R36S)-Fn8-COL 18NC 1 -54 trimer 0 exhibited an apparent molecular weight of ~160Kd while its genuine molecular weight is ~78Kd. GLP-l(A8G/G22E/R36S)-Fn8-COL18NCl trimer exhibited an apparent molecular weight of ~100Kd while its genuine
molecular weight is ~68Kd. GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl-20, GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -30 exhibited larger apparent molecular weight than their genuine molecular weight as well. Therefore, our method can provide the therapeutic polypeptide with a larger Rg which exhibited increased apparent molecular size on gel filtration profile for longer in vivo half life. Moreover, the flexible linker between the therapeutic polypeptide and the scaffold protein may adjust the Rg of the fusion molecule in a tunable manner.
SEQ ID NO: 12, protein sequence of GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -20, the flexible unstructured linker 2 (20 residues) between Fn8 and COL18NC 1 is underlined. The flexible unstructured linker 1 between GLP-1 and Fn8 (GGGSGG) is also underlined.
HOEGTFTSDVSSYLEEOAAKEFIAWLVKGSGGGGSGGAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKN
FEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEOHESTPLRGRQ TGGGGGSGGGGSGGGGSGGGGS
GASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFR VQLEARTPLPRG
SEQ ID NO: 13, protein sequence of GLP-l(A8G/G22E R36S)-Fn8-COL18NCl -30, the flexible unstructured linker 2 (30 residues) between Fn8 and COL18NC 1 is underlined. The flexible unstructured linker 1 between GLP- 1 and Fn8 (GGGSGG) is also underlined.
HGEGTFTSDVSSYLEEOAAKEFIAWLVKGSGGGGSGGAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPV N
KEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTG
GGGGSGGGGSASSASTGGPSGGGGSGGGGS
GASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
SEQ ID NO: 14, protein sequence of GLP- l(A8G/G22E R36S)-Fn8-COL18NCl-54, the flexible unstructured linker 2 (54 residues) between Fn8 and COL18NC1 is underlined. The flexible unstructured linker I between GLP- 1 and Fn8 (GGGSGG) is also underlined.
HGEGTFTSDVSS YLEEOAAKEFIAWLV GSGGGGSGGAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKN EEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG GGGGSGGGGSTASSASTGGPSGGGGSGGGGSAPSSGSTSGGTAAGGGGSGGGGS GASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFR VQLEARTPLPRG
01723
SEQ ID NO: 21 , protein sequence of GLP- l (A8G/G22E/R36S)-Fn8-COL18NC l-60, the flexible unstructured linker 2 (60 residues) between Fn8 and COL18NC1 is underlined. The flexible unstructured linker 1 between GLP-1 and Fn8 (GGGSGG) is also underlined.
HO GTFTSDVSSYLEEOAA EFIAWLVKGSGGGGSGGAVPPPTDLRFT IGPDT RVTWAPPPSIDLT FLVRYSPV K EEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQ TG GOGSGGGSGGGSTASSASTKGPSGGGSGGGSGGGSAPSSKSTSGGTAAGGGSGGGSGGGS GASSGVRLWATRQA LGQVHEVPEGWLIFVAEQEELYVRVQNGFR VQLEARTPLPRG
Example 1 1 . cA P assay for GLP- 1 activity
Through binding and activating a specific G protein-coupled receptor (GLP- 1 receptor), GLP-1 stimulates the signaling pathway to increase cAMP 5 level in cells. Therefore, measuring the cytoplasmic cAMP level can be an accurate method to evaluate the biological activity of GLP-1. Chinese Hamster Ovary (CHO) cells stably transfected with human GLP- 1 receptor (GLP- 1 R) were generated and named as S-CHO cells. S-CHO cells were propagated in D EM medium with 10% FCS containing 0.05mg/ml G418. Before analysis, s o SCHO cells were grown to 70-80% confluence in 6-well plates at 37°C. The cells were treated 0.2mM 3-isobutyl-l -methylxanthine (IBMX). Cells were incubated with GLP-1 fusion proteins at various concentrations of I nM, 3nM, l OnM, 33nM, Ι ΟΟηΜ for 15 min at 37°C. The cells were then lysed by use of cold lysis buffer. The supernatants of the cell extracts were used for cAMP
1 5 level determinations. The Parameter cAMP ELISA kit from R&D Systems was utilized to measure the cAMP concentrations in the cell lysates. The EC50 values of the GLP-1 fusion proteins were generated by using the software Origin. The GLP- 1 (7-37) peptide (Anaspec) and BSA were used as positive and negative controls. Fig. 4 showed the results of cAMP assays for GLP 1 0 (7-37) peptide, GLP1 (A8G/G22E)-Fn8-C0L18NC 1 fusion protein and GLP l (A8G/G22E)-Fn8-COL 18NCl-54 fusion protein. The data indicated that the fusion of Glpl(A8G/G22E) and the scaffold protein did not affect GLP- 1 activity. As a matter of fact, if the lengths of spacers between GLP-1 mutations and scaffold proteins are increased, the activities of GLP-1 improved. We
25 reasoned that a longer flexible, unstructured linker may provide the GLP-1
peptide with more freedom to interact with the GLP-1 receptor. The EC50 values of a number of GLP-1 containing fusion proteins are listed in Table 1.
Table 1 . The activities of GLP- 1 and GLP- 1 containing fusion proteins
5
Example 12 : The pharmacokinetics studies for GLP- 1 (A8G/G22E/R36S)-Fn8-COL 1 8NC 1 ,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -20,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
i o GLP- 1 (A8G/G22E/R36S)-Fn8-COL 1 8NC 1-54.
To evaluate the pharmacokinetics profiles for the GLP-1 containing fusion proteins generated using the method of the invention, we purified GLP- 1 (A8G/G22E/R36S)-Fn8-COL 18NC 1 ,
GLP-l (A8G/G22E/R36S)-Fn8-COL18NCl -20,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
GLP- 1 (A8G/G22E/R36S)-Fn8-COL18NC 1-54 in PBS buffer, pH 7.2. These fusion proteins were administered on SD(Sprague-Dawley) rats by intraperitoneal injections at the concentration of 0.66mg, 0.72mg, 0.75mg,0.78mg/kg animal respectively. Blood samples were taken at various time points after injections such as 0-min, 30-min, 1 -hour, 2-hour, 4-hour, 8-hour, 24-hour, 48-hour, 3-day, 4-day, 5-day. 7-day, 10-day.. The serum samples were centrifuged and kept at -80°C freezer.
The GLP-1 concentrations within the samples were examined by use of the sandwich ELISA method. The mouse monoclonal antibody against GLP- 1 peptide at the concentration of lug/ml (sc57510, Santa Cruz Biotech) was coated on ELISA plate for 1 hour at room temperature. Then the plate was washed by PBST buffer three times and the wells were blocked by PBS with 10% FBS for 1 hour at room temperature. The plate was washed three times before the serum samples containing GLP-1 fusion proteins were added. The serum samples could be diluted to 20-50 folds before use. The ELISA plate was incubated with the serum samples at room temperature for 1 hour and then washed by PBST buffer five times. Then Fibronectin rabbit ploy clonal antibody (Abeam, ab299) at the concentration of lug/ml in PBST buffer was added to the wells. The plate was washed extensively after incubation of 1 hour at room temperature. The secondary antibody, Goat anti-rabbit IgG HRP conjugated antibody (Beijing ZSGB-Bio company, ZB 5301 ), was added into the wells and the color was developed using TMB (3,3\5,5'-tetramethylbenzidine, BD biosciences, Cat 555214 ). The plate reader (Bio -Rad microplate reader Model 680) was utilized to obtain the OD450 readings. This method has been calibrated using purified proteins first.
Fig. 5 showed the pharmacokinetics profiles of the GLP-1 containing proteins by use of the sandwich ELISA method described above. The pharmacokinetics parameters were obtained by using the WinNonlin software (Table 2). The data clearly showed that the GLP- 1 containing fusion proteins generated by use of the method of the invention exhibited much extended in
vivo half life possibly due to their enlarged Rg. The data also showed that the flexible, unstructured linker between the therapeutic polypeptide and the scaffold protein may adjust the in vivo half life of the fusion molecules in a tunable manner.
Table 2. Pharmacokinetics parameters for the GLP-1 containing fusion proteins in Sprague-Dawley rat. GLP-1 (A8G/G22ER36S)-Fn8-COL18NCl, GLP- 1 (A8G/G22E/R36S)-Fn8-COLl 8NC 1 -20,
GLP- 1 ( A8G/G22E/R36S)-Fn8-COL 18NC 1 -30,
GLP-l(A8G/G22E/R36S)-Fn8-COL18NCl-54 were shown in abbreviation as NCl,NCl-20,NCl-30,NCl-54.
Example 13. Cloning of human parathyroid hormone (PTH) fused with COL18NC1
Human parathyroid hormone (PTH) has been shown to stimulate the bone mass significantly. The peptide PTH(l-34) and full length PTH(l-84) are currently used in the treatment of osteoporosis. The half life of human
PTH(l-34) and PTH(l-84) in circulation is quite short, which limits their applications49. In this invention, we applied the method of the invention on human PTH(l-34) and PTH(l-84) by fusing human PTH(l-34) and PTH(l-84) with human collagen XVIII NCI (COL18NC1). The synthetic genes encoding human PTH(l-34) and PTH(l-84) were digested by Ndel and BamWl and ligated into the digested vector pET29b- COL18NC1 (generated in example
1) to construct the fusion genes PTH(l-34)-COL18NCl and
PTH-COL18NC1. The protein sequences of PTH(l-34)-COLl 8NC1 and
PTH-COL1 8NC 1 are listed as SEQ ID NO: 15 and 16. The recombinant PTH( l -34)-COL1 8NC l and PTH-COL 18NC 1 have been prepared and the purities of the proteins were examined by SDS-PAGE analysis (purity>95%). The biological acitivities of these proteins were measured by use of the cAMP assay. PTH can interact with the PTH receptor to stimulate the cAMP production. The cAMP assay was carried out as described in example 1 1 except that the rat osteosarcoma cell line UMR- 106 (ATCC) was utilized in the assay. The results indicated that the biological activity of PTH( l -34)-COL 1 8NC l and PTH-COL1 8NC1 were similar as that of the PTH( l -34) polypeptide. The data showed that the fusion proteins PTH( l -34)-COL 1 8NCl and PTH-COL 18NC 1 retained the biological activity to interact with PTH receptor to stimulate the signaling pathway.
SEQ ID NO: 15, PTH( l -34)-COLl 8NC 1 protein sequence. The unstructured linker region GGGGSGG between PTHQ-34) and CQL18NC1 is underlined.
SVSEIQLMHNLG HLNSMERVEWLRKKLQDVHNF
GGGGSGGGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
SEQ ID NO: 16, PTH-COL18NC 1 protein sequence. The linker region between PTH and COL18NC1 is underlined. The unstructured linker region GGGGSGG is underlined.
SVSEIQLMHNLGKHLNS ERVEWLRKKLQDVHNFVALGAPLAP DAGSQRP KKEDNVLVESHE SLGEADKADVNVLTKAKSQ GGGGSGGGAS5GVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
Example 14. Cloning of Calcitonin fused with COL18NC1
Calcitonin inhibits bone removal by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass It has been shown that Salmon calcitonin is more effective than human calcitonin. The Salmon calcitonin (sCT) is currently used in the treatment of osteoporosis. The half life of calcitonin in human circulation is short (-50 minutes), which limits its applications. In this invention, we fused
salmon calcitonin with the human collagen XVIII NCI (COL18NC 1 ). The synthetic gene encoding salmon calcitonin was digested by Ndel and BamHl and ligated into the digested vector pET29b- COL1 8NC 1 (generated in example 1 ) to construct the fusion gene sCT-COL 18NC l . The protein sequence of sCT-COLl 8NC 1 was listed as SEQ ID NO: 17.
SEQ ID NO: 17, sCT-COL 18NC l protein sequence. The unstructured linker region GGGGSGG between sCT and COL18NC 1 is underlined.
CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP
GGGGSGGGASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
Example 1 5 : Construction of the fusion protein of TNFR2 and COL 1 8NC1 TNF Receptor (TNFR2, or p75) has been fused to IgG l Fc fragment to constitute a fusion protein Etanercept (Enbrel). Etanercept has been successfully utilized to treat severe active rheumatoid arthritis by blocking the TNF alpha functions50. In this example, we applied the method of the invention on TNFR2 to generate the TNFR2-COL18NC 1 fusion protein. TNFR2-COL 1 8NC 1 fusion protein is tri-valent and can block all three binding sites of TNFalpha while retaining a long half life in vivo. On the other hand, one Etanercept molecule can only block two out of three possible binding sites located on TNF alpha homo-trimer. A flexible unstructured linker of 60 residues was utilized to connect TNFR2 and COL 18NC1 in the fusion protein. The gene that encoded the protein sequence ID: 18 was synthesized and sub-cloned into pET29b by Ndel and Xhol.
SEQ ID NO: 18. TNFR2-COL 18NC 1 protein sequence. The flexible unstructured linker between TNFR2 and COL18NC 1 is underlined.
LPAQVAFTPYAPEPGSTCRLREYYDQTAQ CCS CSPGQHAKVFCTKTSDTVCDSCEDST YTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLR CRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNWAIPGNASMDAVCTS TSPT
GGGSGGGSGGGSTASSAST GPSGGGSGGGSGGGSAPSSKSTSGGTAAGGGSGGGSGGGS GASSGV LWATRQAMLGQVHEVPEGWLIFVAEQEELYV VQNGFRKVQLEA TPLPRG
The protein expression of TNFR2-COL1 8NC 1 was carried out as described in example 3. Most of the fusion protein TNFR2-COL1 8NC 1 was expressed as the inclusion bodies. The inclusion bodies were washed extensively by use of 50mM Tris buffer (pH8.0), NaCl 150mM, EDTA 5mM, Tween20 0. 1 %. The inclusion bodies were dissolved in 50mM Tris buffer (pH8.0), Urea 8M, DTT 50mM, NaCl 150mM. The denatured protein was cleared by high speed centrifugation (1 5,000g) for 15 minutes and the protein concentration was adjusted to 0.5mg/ml. The protein refolding was carried out by dialysis against 50mM Tris buffer (pH 8.5), NaCl 1 50mM, I mM EDTA, 2mM Cystine, PEG3350 0. 1 %, L-Arginine 50mM and Tween20 0.05%. The refolding was allowed at 4°C for three days. The refolded TNFR2-COL 1 8NC 1 fusion protein was further purified by use of Hitrap SP HP column and gel filtration column Superdex 200 (GE Healthcare). The purified protein was kept in 20mM Hepes buffer (pH 7.5), NaCl 1 50mM. The purity of the fusion protein was examined by SDS-PAGE electrophoresis (purity >95%).
The biological activity of TNFR2-COL 1 8NC 1 was measured by its ability to block the TNFalpha signaling. Our data indicated that TNFR2-COL 1 8NC 1 can inhibit the cell killing activity of TNFalpha for L929 cells as efficiently as TNFR2-IgG l Fc fusion protein.
Example 16: Construction of the fusion protein VEGFRl R2 and COL 1 8NC 1
Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis such as cancer. Numerous studies suggested that inhibiting VEGF functions may be an efficient treatment for cancer patients. VEGF-Trap was created by fusing the second Ig domain of VEGF receptor 1 (VEGFRl) with the third Ig domain of VEGF receptor 2 (VEGFR2) and the Fc fragment of IgG 51. VEGF-trap has high affinity to VEGF and has shown promising anti-cancer efficacy in clinical trials. In this example, we constructed a novel fusion protein VEGFR l R2 that consists of human VEGFRl second Ig domain and human VEGFR2 third Ig domain. Then we applied the method of the invention to VEGFR l R2 to generate a tri-valent VEGFR 1 R2-COL 1 8NC 1 fusion protein. A flexible unstructured linker of 60 residues was utilized to connect the VEGFR 1 R2 and COL 1 8NC 1 in the construct.
The synthetic gene that encodes the human VEGFR 1 R2-COL 1 8NC I was grafted into the digested vector pET29b by use of Ndel and Xhol. The protein sequence of VEGFR1 R2-COL1 8NC 1 fusion protein was listed as SEQ ID NO: 19.
The expression and refolding of VEGFR 1 R2-COL 1 8NC 1 was carried out using the similar protocol as described in example 15. The purity of the fusion protein was examined by SDS-PAGE electrophoresis (purity >95%). The biological activity of VEGFR 1 R2-COL 1 8NC1 fusion protein was shown by its ability to interact with VEGF. Our data from SPR by use of Biacore indicated that VEGFR 1 R2-COL 1 8NC1 fusion protein can bind VEGF with the similar affinity as the VEGFR l R2-IgG Fc fusion protein.
SEQ ID NO: 19, VEGFR1 R2-COL18NC 1 fusion protein sequence. The flexible unstructured linker region between VEGFR1 R2 and COL18NC1 is underlined.
SDTG PFVEMYSEIPEIIHMTEG ELVIPCRVTSPNITVTLKKFPLDTLIPDGK IIWDSRKGFIISNATYKEIGLLT
CEATVNGHLYKTNYLTHRQGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDL
TQSGSEMKKFLSTLTIDGITRSDQGLYTCAASSGLMTKKNSTFVRVHE
GGGSGGGSGGGSTASSAST GPSGGGSGGGSGGGSAPSSKSTSGGTAAGGGSGGGSGGGS GASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
Example 17: Construction of the fusion protein of human RANK and COL1 8NC 1
In many bone loss conditions, RANK Ligand (RANKL) overwhelms the body's natural defenses against bone destruction 52. Therefore, blocking the RANKL functions has been utilized to treat osteoporosis. For example, the monoclonal antibody Denosumab is designed to target RANKL, and it has been approved by FDA to treat osteoporosis. It has been shown that RANK extra-cellular domain can interact with RANKL with high affinity (Kd~60pM) \ RNAKL forms a homo-trimer in solution and RANK extra-cellular domain forms a monomer. In this example, RANK was clustered into a homo-tnmer by use of the method of the invention to interact with RANKL. A flexible unstructured linker of 60 residues was utilized to connect RANK extra-cellular domain with COL 18NC1 in this example.
The RANK-COL 18NC1 fusion gene was synthesized and sub-cloned into pET29b for expression. The protein sequence of RANK-COL 1 8NC 1 fusion protein was listed as SEQ ID NO: 20.
The expression and refolding of RANK-COL 1 8NC 1 was carried out using the similar protocol as described in example 15. The purity of the fusion protein was examined by SDS-PAGE electrophoresis (purity >95%). The biological activity of RANK-COL 1 8NC 1 fusion protein was shown by its ability to interact with RANK ligand. Our data from SPR by use of Biacore indicated that RANK-COL1 8NC 1 fusion protein can interact with
RANK ligand with the similar affinity as the RANK extracellular domain-IgG Fc fusion protein.
SEQ ID NO: 20, RANK-COLl 8NC1 fusion protein sequence. The flexible unstructured linker region between RANK and COL18NC1 is underlined. α!ΑΡΡ 5ΕΚΗΥΕΗίαΒ00 ΚαΕΡΟ ΥΜ55 0ΤΤΤ5Ο5ναίΡ0ΟΡΟΕΥίΟ5\ΛΝΕΕΟΚ€ΙίΗΚνα0Τ6ΚΑί Α νΑ6Ν5
PRRCACTAQYHWSQDCECCRRNTECAPGLGAQHPLQLN DTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTE
KSDAVCSSSLPA
GGGSGGGSGGGSTASSASTKGPSGGGSGGGSGGGSAPSSKSTSGGTAAGGGSGGGSGGGS GASSGVRLWATRQAMLGQVHEVPEGWLIFVAEQEELYVRVQNGFRKVQLEARTPLPRG
Cited patents:
1 . United States Patent 7557183 Polyethylene glycol linked GLP-1 compounds
2. United States Patent 8093356 Pegylated human interferon polypeptides
3. United States Patent 8058398 Modified G-CSF polypeptide
4. United States Patent 7052686 Pegylated interleukin-10
5. United States Patent 8030269 Calcitonin drug-oligomer conjugates, and uses thereof
6. United States Patent Application 20090325865 Liquid Formulations of Pegylated Growth Hormone
7. United States Patent 8053561 Pegylated factor VIII
8 United States Patent 8053410 Pegylated factor VII glycoforms
9. United States Patent Application 20090312236 PEGYLATED INSULIN LISPRO COMPOUNDS
10. United States Patent 7271 149 GLP- 1 fusion proteins
1 1. United States Patent 6946134 Albumin fusion proteins
12. United States Patent 7785599 Albumin fusion proteins
Cited literatures:
1. Molineux, G. Pegylation: engineering improved biopharmaceuticals for 5 oncology. Pharmacotherapy 23, 3S-8S (2003).
2. Crawford, J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 28 Suppl A, 7- 1 1 (2002).
3. Pasut, G. & Veronese, F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 61 , 1 177-88 s o (2009).
4. Veronese, F.M. & Mero, A. The impact of PEGylation on biological therapies. BioDrugs 22, 315-29 (2008).
5. Eliason, J.F. Pegylated cytokines: potential application in immunotherapy of cancer. BioDrugs 15, 705- 1 1 (2001 ).
! 5 6. Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide- 1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26, 287-96.
7. Picha, K.M. et al. Protein engineering strategies for sustained glucagon-like peptide- 1 receptor-dependent control of glucose homeostasis. 0 Diabetes 57, 1926-34 (2008).
8. Bush, M A. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide- 1 mimetic, in healthy subjects. Diabetes Obes Metab 1 1 , 498-505 (2009).
9. Matthews, J.E. et al. Pharmacodynamics, pharmacokinetics, safety, and 5 tolerability of albiglutide, a long-acting glucagon-like peptide- 1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93, 4810-7 (2008).
10. Ricard-BIum, S. & Ruggiero, F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol (Paris) 53, 430-42 (2005).
30 1 1 . Khoshnoodi, J., Cartailler, J. P., Alvares, K., Veis, A. & Hudson,
B. G. Molecular recognition in the assembly of collagens: terminal noncollagenous domains are key recognition modules in the formation of triple
helical protomers. J Biol Chem 281 , 381 17-21 (2006).
12. Gordon, M.K. & Hahn, R.A. Collagens. Cell Tissue Res 339, 247-57.
13. Shoulders, M.D. & Raines, R.T. Collagen structure and stability. 5 Annu Rev Biochem 78, 929-58 (2009).
14. Wirz, J. A., Boudko, S.P., Lerch, T.F., Chapman, M.S. & Bachinger, H P. Crystal structure of the human collagen XV trimerization domain: a potent trimerizing unit common to multiplexin collagens. Matrix Biol 30, 9-15.
15. Boudko, S.P. et al. The NC2 domain of collagen IX provides chain ! o selection and heterotrimerization. ./ Biol Chem 285, 23721 -31 .
16. Boudko, S.P., Engel, J. & Bachinger, H.P. Trimerization and triple helix stabilization of the collagen XIX NC2 domain. J Biol Chem 283, 34345-5 1 (2008).
17. Kvansakul, M., Bogin, O., Hohenester, E. & Yayon, A. Crystal 1 5 structure of the collagen alphal (VIII) NCI trimer. Matrix Biol 22, 145-52
(2003).
18. Bogin, O. et al. Insight into Schmid metaphyseal chondrodysplasia from the crystal structure of the collagen X NCI domain trimer. Structure 10, 165-73 (2002).
?.o 19. Sundaramoorthy, M., Meiyappan, M., Todd, P. & Hudson, B.G.
Crystal structure of NC I domains. Structural basis for type IV collagen assembly in basement membranes. J Biol Chem 277, 31 142-53 (2002).
20. Boudko, S.P. et al. Crystal structure of human collagen XVIII trimerization domain: A novel collagen trimerization Fold. J Mol Biol 392,
25 787-802 (2009).
21. Ghai, R. et al. Cl q and its growing family. Immunobiology 212, 253-66 (2007).
22. Schaffler, A. & Buechler, C. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab 23 , 194-204.
30 23. Kishore, U. & Reid, K.B. Clq. structure, function, and receptors.
Immunopharmacology 49, 159-70 (2000).
24. Farrah, T. & Smith, C.A. Emerging cytokine family. Nature 358,
26 ( 1992).
25. Cabal-Hierro, L. & Lazo, P.S. Signal transduction by tumor necrosis factor receptors. Cell Signal 24, 1297-305.
26. Zelensky, A.N. & Gready, J.E. The C-type lectin-like domain superfamily. FEBS J 272, 6179-217 (2005).
27. Feinberg, H., Powlesland, A S., Taylor, M E. & Weis, W.I. Trimeric structure of langerin. J Biol Chem 285, 13285-93.
28. Hakansson, K., Lim, N.K., Hoppe, H.J. & Reid, K B. Crystal structure of the trimeric alpha-helical coiled-coil and the three lectin domains of human lung surfactant protein D. Structure 7, 255-64 (1999).
29. Ng, K.K. et al. Orientation of bound ligands in mannose-binding proteins. Implications for multivalent ligand recognition. J Biol Chem 277, 1 6088-95 (2002).
30. Nielsen, B.B. et al. Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an alpha-helical coiled coil. FEBS Lett 412,
388-96 ( 1997).
31 . Hoist, J.J., Vilsboll, T. & Deacon, C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297, 127-36 (2009).
32. Baggio, L.L. & Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131 -57 (2007).
33. Connaris, H., Crocker, P.R. & Taylor, G.L. Enhancing the receptor affinity of the sialic acid-binding domain of Vibrio cholerae sialidase through multivalency. J Biol Chem 284, 7339- 1 (2009).
34. Kim, D., Yan, Y., Valencia, C.A. & Liu, R. Heptameric Targeting Ligands against EGFR and HER2 with High Stability and Avidity. PLoS One
7, e43077.
35. O'Reilly, M.K. & Paulson, J.C. Multivalent ligands for siglecs. Methods Enzymol 478, 343-63.
36. Schellenberger, V. et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27,
1 186-90 (2009).
37. Pankov, R. & Yamada, K.M. Fibronectin at a glance. J Cell Sci 1 15,
01723
3861 -3 (2002).
38. Mao, Y. & Schwarzbauer, J.E. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol 24, 389-99 (2005).
39. Leahy, D.J., Aukhil, I. & Erickson, H.P. 2.0 A crystal structure of a 5 four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84, 155-64 (1996).
40. de Pereda, J.M., Wiche, G. & Liddington, R.C. Crystal structure of a tandem pair of fibronectin type III domains from the cytoplasmic tail of integrin alpha6beta4. EMBO J I S, 4087-95 (1999).
! 0 41 . Wada, K., Wada, Y., Ishibashi, F., Gojobori, T. & Ikemura, T.
Codon usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res 20 Suppl, 21 1 1 -8 (1992).
42. urjan, J. & Herskowitz, I. Structure of a yeast pheromone gene (MF alpha): a putative alpha-factor precursor contains four tandem copies of
! 5 mature alpha-factor. Cell 30, 933-43 ( 1982).
43. Schultz, L.D. et al. Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus. Gene 54, 1 13-23 ( 1987).
44. Burcelin, R. et al. Encapsulated, genetically engineered cells, 0 secreting glucagon-like peptide- 1 for the treatment of non-insulin-dependent diabetes mellitus. Ann N YAcad Sci 875, 277-85 ( 1999).
45. Diez, J.J. & Iglesias, P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148, 293-300 (2003).
5 46. Shapiro, L. & Scherer, P.E. The crystal structure of a complement-l q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8, 335-8 (1998).
47. Ip, W.K., Takahashi, ., Ezekowitz, R.A. & Stuart, L.M. Mannose-binding lectin and innate immunity. Immunol Rev 230, 9-21 (2009). 30 48. Takahashi, K. & Ezekowitz, R.A. The role of the mannose-binding lectin in innate immunity. Clin Infect Dis 41 Suppl 7, S440-4 (2005).
49. Bieglmayer, C, Prager, G. & Niederle, B. Kinetic analyses of
parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy. Clin Chem 48, 1731-8 (2002).
50. Aaltonen, K.J. et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7, e30275.
51 . Stewart, M.W. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets 10, 497-508.
52. McClung, M R. et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354, 821 -31 (2006).
53. Liu, C. et al. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol 1 84, 6910-9.
Claims
1 . A fusion protein comprising a therapeutic polypeptide fused to a scaffold protein which forms a homo-trimer in solution, wherein the therapeutic polypeptide is connected with the scaffold protein via a spacer, and the spacer comprises a flexible un-structured linker whose length is adjustable.
2. The fusion protein of claim 1 , wherein the spacer further comprises a proteinous connecting moiety.
3. The fusion protein of claim 2, wherein the proteinous connecting moiety is a proteinous sequence having an elongated shape.
4. The fusion protein of any of claims 1 -3, wherein the proteinous connecting moiety is connected with the therapeutic polypeptide and/or the scaffold protein via a flexible un-structured linker.
5. The fusion protein of any of claims 1 -4, wherein the fusion protein comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a first flexible un-structured linker, a proteinous connecting moiety, a second flexible un-structured linker, and the scaffold protein.
6. The fusion protein of any of claims 1 -4, wherein the fusion protein comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a proteinous connecting moiety, the flexible un-structured linker, and the scaffold protein.
7. The fusion protein of any of claims 1-4, wherein the fusion protein comprises, from N-terminus to C-terminus, the scaffold protein, a first flexible un-structured linker, a proteinous connecting moiety, a second flexible un-structured linker, and the therapeutic polypeptide.
8. The fusion protein of any of claims 1 -4, wherein the fusion protein comprises, from N-terminus to C-terminus, the scaffold protein, a proteinous connecting moiety, the flexible un-structured linker, and the therapeutic polypeptide.
9. The fusion protein of any of claims 1 -8, wherein the scaffold protein is selected from the group consisting of human collagen noncollagenous (NC) domains which form stable homo-trimers in solution, proteins which form
homo-trimers in solution with Cl q-like molecular structures, proteins which form homo-trimers in solution with TNF-like molecular structures, and proteins with C-type lectin-like domains (CTLD) which form homo-trimers in solution.
5 10. The fusion protein of any of claims 1 -8, wherein the scaffold protein is selected from the group consisting of the NCI domain within Multiplexin type of human Collagen, NC2 domain within FACIT type of collagen, human Cl q A chain, Cl q B chain, Cl q C chain, cbln family members, human EMILIN- 1 , multimerin, ACRP30/adiponectin, adipolin, resistin, resistin-like
1 0 molecule (RELM) hormone family members, human TNFalpha, TNFbeta, TRAIL, RANK ligand, Fas ligand, CD 30 ligand, CD40 ligand, CD27 ligand, OX40L, CD 137, mannan-binding lectin (MBL), surfactant protein A (SP-A), surfactant protein D (SP-D), collectin liver 1 (CL-L1 ), collectin placenta 1 (CL-P 1 ), conglutinin, collectin of 43 kDa (CL-43) and collectin of 46 kDa
] 5 (CL-46), Langerin, Tetranectin and functional variants thereof.
1 1. The fusion protein of any of claims 1 -10, wherein the therapeutic polypeptide is connected to the N-terminus or C-terminus of the scaffold protein.
12. The fusion protein of any of claims 1-1 1 , wherein the therapeutic 0 polypeptide is selected from the group consisting of human glucagon-like peptide-1 (GLP- 1 ), Calcitonin, human Parathyroid hormone (PTH), G-CSF, GM-CSF, Interferon, VEGF receptors, TNF alpha receptors, RANK, Growth hormone, Erythropoietin, single-chain Fv, single domain antibodies and functional variants thereof.
5 13. The fusion protein of any of claims 1-12, wherein the flexible un-structured linker is rich in G, S, A, T or P.
14. The fusion protein of claim 13, wherein the flexible un-structured linker is selected from the group consisting of (G4S)n, (G3S)n, (G2S2)n, where n is an integer, GGGS, GGGSGGGG, GGGSGGGGS, GSGG, 0 GGGSGGG, GGGGSGGG, GGGSGG, GGGGSGG,
GGGGSGGGGSGGGGSGGGGS,
GGGGSGGGGSASSASTGGPSGGGGSGGGGS,
GGGGSGGGGSTASSASTGGPSGGGGSGGGGSAPSSGSTSGGTAAGGG GSGGGGS and GGGSGGGSGGGSTASSASTKGPSGGGSGGGSGGGSAPSSKSTSGGTAA GGGSGGGSGGGS.
5 15. The fusion protein of any of claims 1-14, wherein the length of the flexible un-structured linker is within the range of 5 to 100 amino acid residues.
16. The fusion protein of any of claims 1 -15, wherein the proteinous connecting moiety is human Fibronectin type III domain.
1 0 17. The fusion protein of claim 16, wherein the human Fibronectin type
III domain is selected from the group consisting of Tenascin, Usherin, Titin, tripartite motif (TRIM) family members, tissue factor, TIEl , TIE2, SPEG, SORL 1 , SDK 1 , ROBOl , ROB02, SDK2, Receptor-type tyrosine-protein phosphatase, prolactin receptor, LI CAM, NCAM1 , NCAM2, myomesin 1 ,
1 5 myomesin 2, Myosin-binding protein C, LIFR, Leptin receptor, Integrin, Insulin receptor, Contactin, Collagen, Cytokine receptor-like factor, Inteferon receptor, Growth hormone receptor, fibronectin, leucine rich transmembrane protein (FLRT) members, IL, ephrin type-A receptor, ephrin type-B receptor, IL-6R, gpl 30, IL1 1 RA, IL12RB, IL20RB, IL23R, IL27RA and IL31 RA.
?.o 18. The fusion protein of any of claims 1- 17, wherein the fusion protein comprises: a therapeutic polypeptide selected from the group consisting of GLP- 1 , GLP 1 (A8G/G22E) and GLP1 (A8G/G22E/R36S); a first flexible un-structured linker; a proteinous connecting moiety selected from the group consisting of human fibronectin type III domain 7 (Fn7), human fibronectin
25 type III domain 8 (Fn8), and human Tenascin C fibronectin type III domain 3 (TNCfn3); a second flexible un-structured linker; and a scaffold protein selected from the group consisting of COL18NC1 , COL15NC1 , COL19NC2, ACRP30 Cl q-like domain, and MBL neck and CRD domain.
19. The fusion protein of any of claims 1- 17, wherein the fusion protein 30 comprises: GLP- 1 (A8G/G22E/R36S), a first flexible un-structured linker,
Fn8, a second flexible un-structured linker, and COL1 8NC1 .
20. The fusion protein of claim 1 , wherein the fusion protein is selected
from the group consisting of SEQ ID NO: 1 -21.
21 . A polynucleotide sequence encoding the fusion protein of any of claims 1 -20
22. An expression vector comprising the polynucleotide sequence of claim 21 and expression control elements.
23. A pharmaceutical composition comprising the fusion protein of any of claims 1 -20 and a pharmaceutically acceptable carrier.
24. A method of improving the pharmacokinetic property of a therapeutic polypeptide, comprising the step of fusing the therapeutic polypeptide to a scaffold protein which forms a homo-trimer in solution, wherein the therapeutic polypeptide is connected with the scaffold protein via a spacer, and the spacer comprises a flexible un-structured linker whose length is adjustable to adjust the apparent molecular size and/or the in vivo half life of the fusion protein.
25. The method of claim 24, wherein the spacer further comprises a proteinous connecting moiety..
26. The method of claim 25, wherein the proteinous connecting moiety is a proteinous sequence having an elongated shape.
27. The method of any of claims 24-26, wherein proteinous connecting moiety is connected with the therapeutic polypeptide and/or the scaffold protein via a flexible un-structured linker.
28. The method of any of claims 24-27, wherein the fusion protein comprises, from N-terminus to C-terminus, the therapeutic polypeptide, a first flexible un-structured linker, a proteinous connecting moiety, a second flexible un-structured linker, and the scaffold protein.
29. The method of any of claims 24-28, wherein the scaffold protein is selected from the group consisting of human collagen noncollagenous (NC) domains which form stable homo-trimers in solution, proteins which form homo-trimers in solution with C l q-like molecular structures, proteins which form homo-trimers in solution with TNF-like molecular structures, and proteins with C-type lectin-like domains (CTLD) which form homo-trimers in solution.
30. The method of claim 29, wherein the scaffold protein is selected from the group consisting of the NCI domain within Multiplexin type of human Collagen, NC2 domain within FACIT type of collagen, human Cl q A chain, Cl q B chain, Cl q C chain, cbln family members, human EMILIN-1 , multimerin, ACRP30/adiponectin, adipolin, resistin, resistin-like molecule (RJELM) hormone family members, human TNFalpha, TNFbeta, TRAIL, RANK ligand, Fas ligand, CD 30 ligand, CD40 ligand, CD27 ligand, OX40L, CD137, mannan-binding lectin (MBL), surfactant protein A (SP-A), surfactant protein D (SP-D), collectin liver 1 (CL-L 1), collectin placenta 1 (CL-P1 ), conglutinin, collectin of 43 kDa (CL-43) and collectin of 46 kDa (CL-46), Langerin, Tetranectin and functional variants thereof.
31. The method of any of claims 24-30, wherein the therapeutic polypeptide is connected to the N-terminus or C-terminus of the scaffold protein.
32. The method of any of claims 24-31 , wherein the therapeutic polypeptide is selected from the group consisting of human glucagon-like peptide- 1 (GLP- 1 ), Calcitonin, human Parathyroid hormone (PTH), G-CSF, GM-CSF, Interferon, VEGF receptors, TNF alpha receptors, RANK, Growth hormone, Erythropoietin, single-chain Fv, single domain antibodies, and functional variants thereof.
33. The method of any of claims 24-32, wherein the flexible un-structured linker is rich in G, S, A, T or P.
34. The method of claim 33, wherein the flexible un-structured linker is selected from the group consisting of (G4S)n, (G3S)n, (G2S2)n, where n is an integer, GGGS, GSGG, GGGSGGGG, GGGSGGGGS, GGGSGGG, GGGGSGGG, GGGSGG, GGGGSGG, GGGGSGGGGSGGGGSGGGGS, GGGGSGGGGSASSASTGGPSGGGGSGGGGS,
GGGGSGGGGSTASSASTGGPSGGGGSGGGGSAPSSGSTSGGTAAGGG GSGGGGS and
GGGSGGGSGGGSTASSASTKGPSGGGSGGGSGGGSAPSSKSTSGGTAA GGGSGGGSGGGS.
35. The method of any of claims 24-34, wherein the length of the flexible
un-structured linker is within the range of 5 to 100 amino acid residues.
36. The method of any of claims 24-35, wherein the proteinous connecting moiety is human Fibronectin type III domain.
37. The method of claim 36, wherein the human Fibronectin type III domain (Fn) is selected from the group consisting of Tenascin, Usherin, Titin, tripartite motif (TRIM) family members, tissue factor, ΤΓΕ1, TIE2, SPEG, SORL 1 , SDK1 , ROBOl , ROB02, SDK2, Receptor-type tyrosine-protein phosphatase, prolactin receptor, LI CAM, NCAM1 , NCAM2, myomesin 1 , myomesin 2, Myosin-binding protein C, LIFR, Leptin receptor, Integrin, Insulin receptor, Contactin, Collagen, Cytokine receptor-like factor, Inteferon receptor, Growth hormone receptor, fibronectin, leucine rich transmembrane protein (FLRT) members, IL, ephrin type-A receptor, ephrin type-B receptor, IL-6R, gpl30, IL 1 1RA, IL 12RB, IL20RB, IL23R, IL27RA and IL3 1 RA.
38. The method of any of claims 24-37, wherein the fusion protein obtained thereby comprises: a therapeutic polypeptide selected from the group consisting of GLP-1 , GLP 1 (A8G/G22E) and GLP1 (A8G/G22E/R36S); a first flexible un-structured linker; a proteinous connecting moiety selected from the group consisting of Fn7, Fn8 and TNCfn3; a second flexible un-structured linker; and a scaffold protein selected from the group consisting of COL18NC1 , COL 15NC1 , COL19NC2, ACRP30 Cl q-like domain, and MBL neck and CRD domain.
39. The method of any of claims 24-37, wherein the fusion protein obtained thereby comprises: GLP 1 (A8G/G22E/R36S), a first flexible un-structured linker, Fn8, a second flexible un-structured linker, and COL1 8NC 1
40. The method of claim 24, wherein the fusion protein obtained thereby is selected from the group consisting of SEQ ID NO: 1 -21.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/001723 WO2014100913A1 (en) | 2012-12-24 | 2012-12-24 | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
US14/655,282 US10246503B2 (en) | 2012-12-24 | 2013-12-19 | Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof |
EP13869513.5A EP2935338A4 (en) | 2012-12-24 | 2013-12-19 | Fusion protein of therapeutic polypeptide with improved pharmacokinetic profile and use thereof |
PCT/CN2013/001602 WO2014101287A1 (en) | 2012-12-24 | 2013-12-19 | Fusion protein of therapeutic polypeptide with improved pharmacokinetic profile and use thereof |
CN201380067873.8A CN104870478B (en) | 2012-12-24 | 2013-12-19 | Therapeutic polypeptide fusion proteins with improved pharmacokinetic properties and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/001723 WO2014100913A1 (en) | 2012-12-24 | 2012-12-24 | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014100913A1 true WO2014100913A1 (en) | 2014-07-03 |
Family
ID=51019612
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/001723 WO2014100913A1 (en) | 2012-12-24 | 2012-12-24 | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
PCT/CN2013/001602 WO2014101287A1 (en) | 2012-12-24 | 2013-12-19 | Fusion protein of therapeutic polypeptide with improved pharmacokinetic profile and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/001602 WO2014101287A1 (en) | 2012-12-24 | 2013-12-19 | Fusion protein of therapeutic polypeptide with improved pharmacokinetic profile and use thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US10246503B2 (en) |
EP (1) | EP2935338A4 (en) |
WO (2) | WO2014100913A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015090234A1 (en) * | 2013-12-19 | 2015-06-25 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin |
WO2021234579A1 (en) * | 2020-05-19 | 2021-11-25 | National Research Council Of Canada | Use of resistin as a trimerization partner for expression of trimeric proteins |
WO2023011957A1 (en) | 2021-08-02 | 2023-02-09 | Basf Se | (3-quinolyl)-quinazoline |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2470559B1 (en) | 2009-08-24 | 2017-03-22 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
JP6383666B2 (en) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | Recombinant factor VIII protein |
PT2814840T (en) | 2012-02-15 | 2020-01-28 | Bioverativ Therapeutics Inc | Factor viii compositions and methods of making and using same |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2015341081A1 (en) | 2014-10-28 | 2017-06-08 | Merck Patent Gmbh | Methods for non-covalent Fc-domain-containing protein display on the surface of cells and methods of screening thereof |
MX2018001497A (en) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same. |
RU2744860C2 (en) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Antibodies and their conjugates |
CN110092835A (en) * | 2018-01-30 | 2019-08-06 | 上海惠盾生物技术有限公司 | A kind of GLP-1 analog-COL3A1 fusion protein |
CN111153965A (en) * | 2018-11-07 | 2020-05-15 | 浙江道尔生物科技有限公司 | Artificial recombinant protein for improving performance of active protein or polypeptide and application thereof |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN114644717A (en) * | 2022-04-15 | 2022-06-21 | 江苏农牧科技职业学院 | Recombinant human glucagon-like peptide-1 and construction method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065402A1 (en) * | 2007-11-30 | 2009-06-03 | Industrial Technology Research Institut | Trimeric collagen scaffold antibodies |
CN102153652A (en) * | 2010-12-10 | 2011-08-17 | 浙江大学 | Expression method and application of fusion protein |
WO2011140086A2 (en) * | 2010-05-03 | 2011-11-10 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5961973A (en) * | 1992-03-06 | 1999-10-05 | Crea; Roberto | Pathogen-targeted biocatalysts |
JP2003524368A (en) * | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | Fusion protein comprising a dimerization domain, a trimerization domain or a tetramerization domain and a complementary heterologous transcriptional activation domain, a transcription repression domain, a DNA binding domain or a ligand binding domain |
US7090976B2 (en) * | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
DE10122140A1 (en) * | 2001-05-08 | 2002-11-28 | Apotech Res & Dev Ltd | Recombinant fusion proteins and their trimers |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
EP1894940A1 (en) * | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
AU2008287340A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
PT3178835T (en) * | 2009-02-03 | 2019-06-19 | Amunix Pharmaceuticals Inc | Extended recombinant polypeptides and compositions comprising same |
EP2470559B1 (en) * | 2009-08-24 | 2017-03-22 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US8557961B2 (en) * | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
EP2420253A1 (en) * | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
EP2441776A1 (en) * | 2010-10-15 | 2012-04-18 | Leadartis, S.L. | Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain |
PE20142451A1 (en) * | 2012-02-27 | 2015-02-04 | Amunix Operating Inc | COMPOSITIONS OF CONJUGATES OF XTEN AND METHODS TO MAKE THEM |
-
2012
- 2012-12-24 WO PCT/CN2012/001723 patent/WO2014100913A1/en active Application Filing
-
2013
- 2013-12-19 EP EP13869513.5A patent/EP2935338A4/en not_active Ceased
- 2013-12-19 WO PCT/CN2013/001602 patent/WO2014101287A1/en active Application Filing
- 2013-12-19 US US14/655,282 patent/US10246503B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065402A1 (en) * | 2007-11-30 | 2009-06-03 | Industrial Technology Research Institut | Trimeric collagen scaffold antibodies |
WO2011140086A2 (en) * | 2010-05-03 | 2011-11-10 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
CN102153652A (en) * | 2010-12-10 | 2011-08-17 | 浙江大学 | Expression method and application of fusion protein |
Non-Patent Citations (2)
Title |
---|
BOUDKO, S. P. ET AL.: "Trimerization and triple helix stabilization of the collagen XIX NC2 domain.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 49, December 2008 (2008-12-01), pages 34345 - 34351 * |
TSILIBARY, E. C. ET AL.: "The role of the main noncollageous domain (NC1) in type IV collagen self-assembly.", THE JOURNAL OF CELL BIOLOGY, vol. 103, no. 6, December 1986 (1986-12-01), pages 2467 - 2473 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015090234A1 (en) * | 2013-12-19 | 2015-06-25 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin |
WO2021234579A1 (en) * | 2020-05-19 | 2021-11-25 | National Research Council Of Canada | Use of resistin as a trimerization partner for expression of trimeric proteins |
WO2023011957A1 (en) | 2021-08-02 | 2023-02-09 | Basf Se | (3-quinolyl)-quinazoline |
Also Published As
Publication number | Publication date |
---|---|
EP2935338A4 (en) | 2017-03-15 |
WO2014101287A1 (en) | 2014-07-03 |
EP2935338A1 (en) | 2015-10-28 |
US10246503B2 (en) | 2019-04-02 |
US20160194370A1 (en) | 2016-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10246503B2 (en) | Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof | |
US11535657B2 (en) | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases | |
KR102493543B1 (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
EP2536757B1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
EP2829550A2 (en) | Fusion proteins forming trimers | |
US11555058B2 (en) | Cells engineered to express ultra-long acting insulin-Fc fusion proteins | |
WO2021011827A1 (en) | Ultra-long acting insulin-fc fusion proteins and methods of use | |
WO2011060583A1 (en) | Nonnatural collagen-like protein and use thereof | |
CN104870478B (en) | Therapeutic polypeptide fusion proteins with improved pharmacokinetic properties and uses thereof | |
WO2022117044A1 (en) | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof | |
WO2015090234A1 (en) | Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin | |
RU2391353C2 (en) | Polypeptide with growth hormone receptor agonist properties, nucleic acid coding said polypeptide, expression vector thereof and cell producing said polypeptide | |
WO2015161832A1 (en) | Long-acting recombinant human interferon α2b-fc fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12890759 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12890759 Country of ref document: EP Kind code of ref document: A1 |